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Welcome Remarks 
Dear Friends and Colleagues, 
On behalf of the I-DSD steering committee, it is with great pleasure that I welcome you to Glasgow 
for the 4th International Symposium on Disorders of Sex Development from the 7th to 9th June 
2013. 
Following the first two meetings in Lübeck in 2004 and 2006, a third meeting was held in 2011 
under the EuroDSD banner. All these three meetings had been very successful in attracting a 
multidisciplinary group of experts who discussed a range of DSD-related issues and laid the 
foundation for international collaboration. In 2011, the UK Medical Research Council funded a 
partnership project (I-DSD) which was aimed at sustaining and extending the partnerships 
developed through the EuroDSD project.  The cornerstone to this collaboration is the I-DSD 
Registry which has registered users from all corners of the world and is fast developing into a 
professional and scientific network. The programme which has been developed focuses on a range 
of research which is being performed in a group of rare conditions such as DSD. The meeting will 
consist of invited speakers and original communications and there will be prizes for the original 
communications. . In addition to the scientific programme, there will be a workshop for 
investigators who are interested in performing clinical research in DSD and for those who would 
like to use the I-DSD Registry. 
Glasgow, a city renowned for being the powerhouse of the British industrial revolution has 
emerged into the 21st century as a city with rich culture and a cosmopolitan outlook. It is one of 
the top UK destinations for tourism and offers visitors access to the best mixture of museums and 
galleries, shopping and outdoor adventures. Glasgow is a highly popular conference venue and, 
this year, the I-DSD meeting will coincide with the annual meeing of RCPCH and Europaediatrics. 
 
The meeting venue is a landmark building that links, within a short walking-distance, the vibrant 
West End of Glasgow to the original university buildings on Gilmorehill, the venue for the 
meeting’s evening dinner and traditional ceilidh. 
 
Whilst in Glasgow, if you cannot see the distant hills, it is usually because it is raining. When you 
can see the hills, it means that it is about to rain! We are hoping that some of you will join us for a 
potentially wet walk in the Loch Lomond area on Sunday afternoon.  
We would like to acknowledge the generous support of the Medical Research Council UK 
So, once again 
                                           Fàilte gu Alba! 
Faisal Ahmed and Jillian Bryce 
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General Information 
 
Meeting Venue: University of Glasgow 
  Sir Charles Wilson Building, corner of Gibson Street and Kelvin Way 
 
Workshop Venue: University of Glasgow 
  Wolfson Medical School, Clinical Skills Suite, University Avenue 
 
Internet: Eduroam  (Requires set up via home institute prior to travel) 
GU Visitor (password issued to registered participants in advance)  
 
Badges: Name badge upon registration.  Permits access to Symposium Sessions and 
catering facilities.  (Does not permit access to DSD workshop - separate 
registration required)  
 
Meals:  Lunches and coffee breaks included in registration fee 
 
Conference Dinner: Included in registration fee but limited numbers therefore entry by ticket 
only (supplied in registration pack). 
 
Accreditation:  Federation of the Royal Colleges of Physicians of the United Kingdom for 18 
category 1 (external) CPD credit(s).  Certificates of Attendance will be 
provided at the Symposium. 
 
Organising  Faisal Ahmed, Jillian Bryce, Karyn Cooper, Martin McMillan, Martina Rodie 
Committee: Ellie Magritte (Family/Support Session), Feyza Darendeliler (DSD Workshop) 
 
Additional Support: Special thanks to the volunteers from Child Health and NeSC for the 
additional ground support 
 
Sponsors:  MRC 
   University of Glasgow 
   Scottish DSD Network 
   Yorkhill Children’s Charity 
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Scientific Programme 
 
Friday 7th June 2013 
Time   Location 
09:00 DSD Training Workshop for New Investigators Wolfson Medical School 
 Facilitator: Feyza Darendeliler (Istanbul) Level 4 Clinical Skills Suite 
 
12.30 Lunch (at DSD Workshop) Wolfson Medical School Foyer 
 
11:30 Symposium Registration Opens  Sir Charles Wilson Building Foyer 
 
12.00 Lunch (at Symposium Registration) Sir Charles Wilson Building Foyer 
13.30 Opening Welcome Sir Charles Wilson Lecture Theatre (LT) 
 Faisal Ahmed (Glasgow) 
 
13:35 Session 1. Priorities for the Future   Sir Charles Wilson LT 
  (Invited Plenary) Chair:  Chris Driver (Aberdeen) 
13.35 I-01 Walking the walk   
  Ellie Magritte (dsdfamilies.org)  
13.50  I-02 The approach to the affected child and family  
  Berenice Mendonca (Sao Paulo)  
14.05 I-03 DSDnet: Formation of an open world-wide network on DSD 
  Olaf Hiort (Luebeck) 
14.20  Discussion 
 
15:00 Coffee break Sir Charles Wilson Building Foyer 
 
15:30 Session 2. Oral Communications Sir Charles Wilson LT 
   Chair: Laura Audi (Barcelona) 
15:30 O-01  Young women with DSD their reported experiences of clinical conversations with 
healthcare professionals.  
  Caroline Sanders (Liverpool) 
15:45 O-02  Clinical and genetic characterization of 232 egyptian DSD patients  
  Inas Mazen (Cairo) 
16:00 O-03  Gender outcome and sexual functioning in Indonesian patients with a disorder of 
sex development (DSD)  
  Annastasia Ediati (Indonesia) 
16:15 O-04  Phalloplasty for men with DSD and micropenis  
  Nina Callens (Ghent) 
16:30 O-05  Management of children with CAH. Time of correction and operation methods of 
virilized genitales and longterm outcome. 
  Gabriele Jergl-Corkin (Ulm) 
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Friday 7th June 2013 
Time   Location 
17:30 Evening Lecture Humanities Lecture Theatre 
  Chair: Ian Ford (Glasgow) 
 Quantification in the quest for normality in paediatrics 
 Prof. Lawrence Weaver (Glasgow) 
18:15  End of Day 1 Free Evening 
 
Saturday 8th June 2013 
Time   Location 
 
09:00 Session 3 Drug-Based Therapeutic Interventions Sir Charles Wilson LT 
  (Invited Plenary) Chair:  Martine Cools (Ghent) 
09.00  I-04  Hydrocortisone replacement in adrenal insufficiency 
  Richard Ross (Sheffield) 
09.20  I-05  Medical therapy for undescended testes 
  Pat Malone (Southampton) 
09.40  I-06  The growth of the hypospadiac genital tubercle 
  Pierre Mouriquand (Lyon) 
10.00  I-07 Sex steroid therapy in AIS 
  Olaf Hiort (Luebeck) 
10.20   Discussion 
 
10.45 Coffee break Sir Charles Wilson Building Foyer 
 
11:15 Session 4 Oral Communications  Sir Charles Wilson LT 
   Chair:  Antonio Balsamo (Bologna) 
11:15 O-06 A Multicenter, Interdisciplinary Disorder of Sex Development Registry  
  Patricia Y. Fechner (Seattle) 
11:30 O-07 Range and Patterns of Associated Conditions in Disorders of Sex Development: 
Findings from the I-DSD Registry  
  Kathryn Cox (Glasgow) 
11:45 O-08 Cardiovascular pathology in males and females with 45,X/46,XY mosaicism  
  Katya De Groote (Ghent) 
12:00 O-09 Copy number determination of sex determining genes by MLPA analysis in 
patients with 46,XY DSD  
  Annalisa Nicoletti (Bologna) 
12:15 O-10 Temporal Changes In Sex Assignment Based On Data Gathered From The I-DSD 
Registry  
  Zofia Kolesinska (Poznan) 
12:30 O-11 Mining a large DSD database: success and failures  
  Rieko Tadokoro Cuccaro (Cambridge) 
12.45 O-12 dsd-Life: Clinical European study on the long-term effects of hormonal and 
surgical therapy and psychological intervention in disorders of sex development  
(DSD) 
  Birgit Köhler (Berlin) 
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Saturday 8th June 2013 
Time  Location 
 
13:00 Poster Session & Lunch Sir Charles Wilson Building Seminar Rooms & Foyer 
 
14:00 Session 5 Care and Communication Sir Charles Wilson LT 
  (Invited Plenary) Chair: Anna Nordenstrom (Stockholm) 
14.00  I-08 Supporting the parents of the newborn child 
  Vickie Pasterski (Cambridge) 
14.20  I-09 What Do We Know About Behavior in Older Children and Adolescents with DSD 
  Amy Wisniewski (Oklahoma) 
14.40  I-10 Applicability of care standards in resource poor countries 
  Jamal Raza (Karachi) 
15.00  I-11 Strengths and weaknesses of current research and future directions 
  David Sandberg (Ann Arbor) 
15.20  Discussion 
 
15.40 Coffee break Sir Charles Wilson Building Foyer 
 
16:00 Session 6 Navigating the Information Highway  Sir Charles Wilson LT 
  (Invited Plenary) Chair:  Liz Crowne (Bristol) 
16.00  I-12 Making sense of the genetic information 
  Ken McElreavy (Paris) 
16.20  I-13 Grappling with steroid metabolomics 
  Nils Krone (Birmingham) 
16.40  I-14 The future of rare disease registries 
  Domenica Taruscio (Rome) 
17.00   Discussion 
 
19:30 Symposium Dinner & Ceilidh Ferguson Room, One A The Square 
 
 
Sunday 9th June 2013 
Time   Location 
 
08:50 Session 7 Management of the Retained Gonad   Sir Charles Wilson LT 
  (Invited Plenary) Chair: Ieuan Hughes (Cambridge) 
08:50  A legal vs medical conflict in management  
  Ieuan Hughes (Cambridge) 
09.00  I-15 The genetics of gonadal development  
  Andrew Sinclair (Melbourne) 
09.20  I-16 The fate of the gonad in DSD 
  Leendert Looijenga (Rotterdam) 
09.40  I-17 Imaging the gonad 
  Margaret Hall-Craggs (London) 
10.00  I-18 The practical management of an adult at risk of gonadal tumourigenesis 
  Gerry Conway (London) 
10.20   Discussion 
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Sunday 9th June 2013 
Time   Location 
 
10.40 Coffee break Sir Charles Wilson Building Foyer 
 
11:00 Session 8 Oral Communications Sir Charles Wilson Lecture Theatre 
   Chair: Ruth McGowan (Aberdeen) 
11:00 O-13 Modeling Testicular Dysgenesis and Endocrine Disruption in the Human Fetal 
Testis  
  Rod Mitchell (Edinburgh) 
11:15 O-14 Refining the sex determining region located upstream from SOX9 gene.  
  Capucine Hyon (Paris) 
11:30 O-15 Preservation of Dysgenetic Gonads - Clinical Outcome  
  Jolanta Slowikowska-Hilczer (Warsaw) 
11:45 O-16 Chromatin profiling of germ cell cancer cell lines reveals differences in active 
enhancer states between Seminomas and Non-seminomas: a GENVIRONMENTAL 
connection?  
  Yvonne van der Zwan (Rotterdam) 
12:00 O-17 Exome sequencing reveals mutations in FOG-2 associated with 46,XY DSD  
  Anu Bashamboo (Paris) 
12:15 O-18 Sexual dimorphism of in vivo rodent brain chemistry using Magnetic Resonance 
Spectroscopy.  
  Martina Rodie (Glasgow) 
 
12:30 Adjudication of Oral Communications (Panel)  
 
12.30 Lunch Sir Charles Wilson Building Foyer 
 
13.30 Loch Lomond Trip Coach Collection Point: University Memorial Gate 
17:00 Coach return from Loch Lomond 
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Poster Presentations Sir Charles Wilson Building Seminar Rooms 
 
P-01  Angela Lucas-Herald 
The outcome of prenatal identification of a sex chromosome abnormality 
 
P-02  Angela Lucas-Herald 
Range of urinary steroid metabolite ratios in children undergoing investigation for suspected disorder of 
steroid synthesis 
 
P-03  Erin Bergner 
News coverage of disorders of sex development, 1993-2012 
 
P-04  Karen Meadley 
Neovagina in patients with Mayer–Rokitansky–Küster–Hauser syndrome. 
 
P-05  Wiebke Birnbaum 
The decision making process in a case of late diagnosed 5a-reductase deficiency 
 
P-06  Sally Tantawy 
Analysis of the gene coding for Steroidogenic Factor 1 (SF-1, NR5A1) in a cohort of fifty Egyptian patients 
with 46,XY disorders of sex development 
 
P-07  Yvonne van der Zwan 
Steroidogenic factor-1 mutations: relation with obesity in humans 
 
P-08  Asmahane Ladjouze 
Clinical heterogeneity in patients with NR5A1/ SF1 mutations: About four cases of Algerian patients 
presenting with 46, XY Disorder of sexual differentiation. 
 
P-09  Nadine Christina Diana Hornig 
Transcription analysis of APOD and PPAP2B in genital skin fibroblasts derived from male controls and AIS 
patients 
 
P-10  Marek Niedziela 
A novel Q117X SRY gene mutation in a 46,XY girl with Swyer syndrome 
 
P-11  Scott Shepherd 
One for Dex and Dex for all: challenges in the management of congenital adrenal hyperplasia (CAH) in a 
multiple pregnancy 
 
P-12  Stefan Riedl 
Discrepant biochemical findings in a SRD5A2-mutation-negative patient with 46,XY-DSD showing a 5-a-
reductase deficiency-typical urinary steroid profile 
 
P-13  Miriam Muscarella 
Words that Matter: Improving Medical Conversations and Resources Around DSD for Patients and Families 
Through Individual Experiences 
 
P-14 Soara Menabò 
46,XX DSD with Prader V virilisation, hormonal “conventional” pattern typical for 21-Hydroxylase deficiency 
(21OHD), and lack of CYP21A2 mutations.
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Support Group Parallel Session 
 
 
Saturday 8th June 2013 
Time   Location 
 
09:00 Support Group Parallel Session Sir Charles Wilson Building Seminar Rooms 
 Chair: Ellie Magritte (dsdfamilies.org) 
 
12:30 Session Ends 
 
 
Meet the Experts – A Joint Effort 
Expertise in dealing with DSD is usually understood as endocrinologists, urologists, psychologists, 
etc. working together as a Multidisciplinary Team. 
 
But aren't we missing out on the most important discipline?  The experts in the everyday life of 
DSD are those affected by DSD and their families. 
 
So what we need when thinking and talking about optimal care, in all its dimensions, is a joint 
effort of both kinds of expertise. 
 
This informal meeting brings together our affected community with a more or less equal number 
of members from the medical community.  
 
 
 
 
This session is primarily by invitation but if you wish to participate please contact the Session Chair, 
Ellie Magritte (info@dsdfamilies.org) 
 
 
Please note that access to the Posters/Displays in this seminar room is suspended for the 
duration of this session.  Access will be permitted from 12.30pm 
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Abstract - Guest Lecture 
Quantification in the quest for normality in paediatrics 
Lawrence Weaver, Emeritus Professor of Child Health 
 
Science is based on observation and experimentation, and fundamental to both are weighing and 
measuring. This talk will explore the origins of quantification in the ‘scientisation’ and 
‘medicalisation’ of child care and the creation of the specialty of paediatrics. 
The nineteenth century saw the incorporation of technology, such as the stethoscope, microscope, 
and thermometer, into clinical medicine. An instrument that has received less attention in the 
history of medicine is the weighing balance. Although not new to nineteenth century medicine, it 
played an important part in the rise of the ‘numerical method’ and the application of 
‘quantification’ to the development and shaping of paediatrics. During its clinical and scientific 
adoption, the simple procedure of weighing babies was refined and applied in a number of 
increasingly sophisticated and far-reaching ways: as a measure of the dimensions of the fetus and 
newborn, as an index of the viability of the newborn, as a means of estimating milk intake, as a 
way of distinguishing normality from abnormality, as a summary measure of infant health, and as 
an instrument of mass surveillance. In so doing it changed the way in which medical care was 
delivered to infants. 
 
 
  
7th-9th June 2013, Glasgow, UK 
12 
 
Abstracts - Invited Speakers 
I-01 Walking the walk 
Ellie Magritte (dsdfamilies.org) 
 
We know that developing optimal care for families, children, young people and adults with a DSD 
demands the input from those who live with these conditions.  
We know it requires a much better understanding of the social context in which we live with these 
conditions. 
We know that psychological care is a crucial part of DSD care.  
We know there is an urgent want of accessible, educational and practical materials.  
We know that long term outcomes for adults appear to be associated with good social support. 
We talk about what we know…but putting what we know into practice is all too often lacking… 
Thanks to a grant of the Yorkhill Hospital Foundation, some 15 adults and parents, representing 
various conditions, will attend the I-DSD conference – creating a long overdue opportunity to 
explore and address users’ needs in a constructive and collaborative environment. To maximise 
interaction over the course of the conference I will start my presentation by introducing all those 
representing the affected community. 
Then, I want to focus on our responsibilities: the responsibility of doctors and parents to care for 
our young children, and to equip them with knowledge and support, resilience and love so that 
they can take over the responsibility for their own health and wellbeing as they grow into the 
contented and self-confident young adults we all want them to be. 
What are the challenges to managing our responsibilities effectively and confidently? And what 
tools can we put in place to do a better job? How can we put all that knowledge we have 
developed, all that experience we have accumulated, to the best use possible? 
We know how to talk the talk, now let’s walk the walk. 
 
I-02 The approach to the affected child and family 
Berenice B Mendonca, MD, Professor of Medicine 
Head of the Division of Endocrinology, University of São Paulo, School of Medicine, São Paulo, 
Brazil  
The birth of a newborn with ambiguous genitalia brings the family and physician’s great concern, 
and this situation must be considered a medical emergency. The first step is to interview the 
parents. It is important to ask them what they know about the child’s problem, which sex do they 
desire and feel the newborn is. The physician's role is to show serenity and assurance; explain to 
the parents the principles of sex development; compare genital ambiguity to other congenital 
malformations; explain that the karyotype does not define gender identity; advice parents on how 
to explain the disease to their family and friends. A detailed clinical history is very important to 
determine if there is consanguinity and presence of similar cases in the family, the ethnicity, the 
use of hormones during pregnancy and the birth weight. On physical examination dysmorphic 
appearance, size of the phallus, position of the urethra, number of perineal orifices, scrotum 
hyperpigmentation and the presence of gonads should be evaluated. Laboratory evaluation 
consists of imaging evaluation and cytogenetic analysis by karyotype or through the presence of 
the SRY gene by PCR or FISH. Baseline serum levels of sodium, potassium, cholesterol and of the 
hormones LH, FSH, AMH, ACTH, 17OHP, PROG, 17OHPREG, DHEAS, androstenedione, cortisol, 11-
deoxycortisol, aldosterone, Renin, T, DHT should also be performed. Stimulation tests with hCG 
4th International Symposium on Disorders of Sex Development 
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and/or ACTH and determination of urinary steroids followed by molecular analysis of candidate 
genes are other tools necessary to clarify the diagnosis in most of these patients.  
My advice to clinicians regarding the approach of DSD patients based in my own experience of 
more than 450 patients. Keep it simple and work with resources for the laboratory diagnosis and 
with a trained multidisciplinary team. Only skilled surgeons with specific training in the surgery of 
DSD should perform these procedures. 
 
 
I-03 DSDnet: Formation of an open world-wide network on DSD 
Olaf Hiort, University of Lübeck, Germany 
 
DSD comprise a heterogeneous group of differences of sex development with at least 40 different 
entities of which most are genetically determined. An exact diagnosis is lacking in 10 to 80% of the 
cases, which constitutes an obstacle for the complex management and the prognosis. The 
European Union has therefore agreed to fund a specific Action in its “Cooperation of Science and 
Technology (COST) programme, to address the following points: To allow the standardisation of 
diagnostic and management aspects through the formation of a European Reference Network on 
DSD; To identify the genetic pathways leading to DSD and create appropriate model systems; To 
inform and communicate about DSD and foster accessibility and improvement of care. This COST 
Action will start in late 2013 and is open to all European countries and also to non-European 
countries. 
 
 
I-04 Hydrocortisone replacement in adrenal insufficiency 
Richard Ross, University of Sheffield, UK 
 
Cortisol secretion follows a distinct circadian rhythm, with circulating levels low at sleep onset, 
beginning to rise between 02.00 hrs and 04.00 hrs, peaking within an hour of waking and then 
declining through the day.  This circadian rhythm is determined by the central endogenous clock 
(pacemaker) of the hypothalamic-pituitary-adrenal (HPA) axis, located in the hypothalamic supra-
chiasmatic nucleus.  The HPA axis plays an important role in maintaining alertness and modulating 
sleep.  Conditions associated with insomnia including depression, sleep apnoea and chronic 
fatigue disrupt the circadian rhythm of cortisol leading to metabolic abnormalities and increased 
cardiovascular risk.  Patients with adrenal insufficiency have lost the normal circadian rhythm of 
cortisol and increased morbidity due to fatigue and excess mortality mainly from cardiovascular 
events and infections.  Patients with congenital adrenal hyperplasia (CAH), have an even greater 
problem because of the challenge of both replacing glucocorticoid and controlling androgen 
excess.  A recent large cohort study in the UK, CaHASE, has revealed evidence of greatly impaired 
health status in adult patients with CAH.  Thus, there is a need for physiological circadian cortisol 
replacement to address some of these issues.  Chronocort is a new approach to delivering 
hydrocortisone therapy.  This modified release formulation replaces the overnight circadian 
rhythm of cortisol.  Pilot formulations have demonstrated the ability to mimic the circadian 
cortisol rhythm in normal volunteers and studies in patients with CAH have confirmed the ability 
to control morning androgen levels.  In conclusion, there is a need to develop new formulations of 
glucocorticoid replacement and chronocort provides one option for addressing this challenge. 
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I-05 Medical Therapy for Undescended Testes 
Pat S Malone, University Hospitals Southampton, UK 
 
The undescended testis (UDT) is one of the commonest abnormalities of genital development, 
affecting approximately 1.5% of boys at one year of age. Testes that remain undescended suffer 
progressive tubular and germ cell damage that ultimately affects spermatogenesis and future 
fertility. Consequently current practice recommends that testes should be brought to the scrotum 
by one year of age, with some recommending surgery as early as 3 months.   
Medical therapy, in the form of HCG, was first used in the management of UDT in an attempt to 
produce testicular descent or to distinguish between retractile and truly undescended testes.  It 
did not work and there was concern that HCG induced apoptotic changes in the germ cells and 
inflammatory changes in the testes. The Nordic consensus on the management of UDT (2007) 
stated that there was no role for the use of endocrine therapy and its use to promote testicular 
descent has been universally abandoned. 
However, adjuvant endocrine therapy may have another role. Multiple studies have clearly 
demonstrated that there is an arrest of spermatogenesis in UDT with a failure to develop adult 
dark spermatogonia  (a surrogate marker of future fertility) even following orchidopexy. The use of 
adjuvant GnRH has been examined in many studies and the majority demonstrated an 
improvement in fertility indices, although the level of evidence is of low quality. This presentation 
will examine this evidence and propose that there is a role for a prospective randomized 
controlled trial to answer this question once and for all. If we consider that paternity rates are as 
low as 65% in men with a history of bilateral UDT, all options must be explored to improve this.  
 
 
I-06 The growth of the hypospadiac genital tubercle 
Pierre Mouriquand, Hospices Civils de Lyon – Université Claude Bernard – Lyon , France 
 
An essential aspect of Paediatric Urology and Paediatric Surgery is that surgeons operate on 
growing tissues. It means the tissues used for any reconstruction particularly genitalia will change 
in size and nature along childhood. It is therefore important to understand how organs grow and 
evaluate the outcome of surgical reconstruction during childhood, puberty and when the full sized 
organ is achieved. 
The growth of Genital Tubercle (GT) in « normal » children and in DSD patients is a fascinating 
example of the complexity of the mechanisms acting on this organ from the prenatal period to 
adulthood. We know  little on the cascade of events interacting with the construction of the GT. 
The aim of this talk is to bring some facts on the construction of the normal and hypospadiac GT 
and its growth after reconstruction.  
What happens for the growth of the hypospadiac GT ? Hypospadias is a development halt of the 
tissues forming the ventral aspect of the GT. The result of this is a triangular defect whose summit 
is the proximal division of the corpus spongiosum, the lateral sides are the atretic pillars of 
spongiosum and the base is the open glans. The tissues sitting inside this triangle do not grow at 
the same pace as the rest of the GT. This fact is recent ly known and probably explains that 
surgical techniques solely using ventral tissues (Thiersch – Duplay, TIP) to repair the missing 
urethra may not have the same satisfactory outcome as urethroplasties combining dorsal and 
ventral tissues (Onlay urethroplasties) or urethroplasties eliminating immature tissues (Koff). 
Preliminary studies on the protein platform of the tissues sitting in the triangular defect seem to 
confirm the imbalance between constructive and destructive proteins and could explain the less 
sensitive androgen response of these tissues.  
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Attempts to improve the surgical outcome of hypospadias surgery  have been mainly based on 
preoperative steroid treatment, essentially androgens. Although effects on androgens on the GT 
growth is well reported, several teams have noticed an increased number of healing complications 
after this preoperative androgen stimulation. It is also reported by dermatologists that estrogens 
improve skin healing performance. A double blind study using Promestrien (topical estrogens) vs. 
Placebo has started two years ago in France and will evaluate the possible differences of 
complications between these two groups. 
 
 
I-07 Sex steroid therapy in androgen insensitivity syndrome 
Olaf Hiort, Division of Paediatric Endocrinology and Diabetes, University of Lübeck, Germany 
 
Androgen insensitivity describes the inability of cells to respond adequately to androgens. The 
clinical aspects are well characterized and described in the androgen insensitivity syndrome (AIS), 
where underandrogenization and feminisation occurs despite normal to high levels of androgens. 
All individuals with AIS have a distinct hormonal pattern with testosterone and estradiol usually in 
the upper male reference interval despite their highly variable phenotype ranging from completely 
female to male.  Sex steroid therapy is used in males to enhance further masculinisation and in 
females if the gonads have been removed.  In females after gonadectomy, usually a mono-therapy 
with continuous estrogens is used for hormone replacement to maintain secondary sexual 
characteristics and to promote physical and social well-being. However, this has been challenged 
by some individuals with the complete form of AIS, who reported that this would not correspond 
to their typical hormone profiles and that they felt diminished in their health-related quality of life. 
Some women with complete AIS have started with a high dose testosterone therapy, but this 
practice remains anecdotal until a recently started double-blind clinical trial employing 
testosterone versus estradiol therapy in complete AIS has been evaluated (www.cais-studie.de). 
The management of hormone therapy in partial AIS and female phenotype and other forms of DSD 
may also change in the near future depending on the outcome of this trial. In males with partial 
AIS, high-dose androgen therapy has been tried with both dihydrotestosterone and testosterone. 
The dose regime needs to be individually assessed and the outcome individually monitored. So far, 
a structured clinical trial has not been performed. Further international studies are needed to 
assess possible endocrine therapies in individuals with AIS and monitor positive and negative 
effects. 
 
 
I-08 Supporting the parents of the newborn child 
Vickie Pasterski, PhD, Department of Paediatrics, University of Cambridge 
 
The experience of having a child born with ambiguous genitalia and/or be diagnosed with a 
disorder of sex development (DSD) is increasingly being understood as a traumatic event for 
parents. Though not all presenting cases are life-threatening, the event may nevertheless be 
experienced as a threat to the integrity of the child. Supporting the parent in this scenario is 
increasingly being incorporated into the clinical care model. In addition, while the distress that 
parents experience has been well documented, evidence-based protocols for relieving parental 
distress are only just emerging. Recent data suggest that uncertainty on the part of the parent(s), 
which can go on for as long as it takes to reach a diagnosis, is predictive of reported levels of stress. 
Uncertainty in terms of the process of typical sexual differentiation and how it relates to a specific 
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diagnosis and prognosis may be alleviated with the provision of educational materials and 
interpersonal support from the multidisciplinary team. However, in some cases, additional 
intervention may be warranted. An evidence based model for treating and supporting families 
which identifies events such as diagnosis and emergent medical care as potentially traumatic 
events and articulates that it is the interaction between the objective nature of the event and the 
subjective interpretation of the event which renders it as traumatic or not may prove useful in 
cases of DSD, but has yet to be tested. Such a model will be discussed along with the potential 
ramifications of uncertainty within the DSD-related medical field itself. For example, the evolution 
of clinical management, including issues pertaining to diagnostic classification, management of 
undiagnosed cases, and approaches to surgical interventions, will be considered. 
 
 
I-9 What do we know about behavior in older children and adolescents with DSD? 
Amy B. Wisniewski, PhD, Department of Urology, The University of Oklahoma Health Sciences 
Center, Oklahoma City, OK, USA 
 
Children with DSD develop aspects of their gender that are discordant with their genetic, 
hormonal and/or social sex.  An explanation of the role of sex chromosomes, androgen exposure 
and learning on the development of gender and other behaviors in children and adolescents with 
46,XX and 46,XY DSD will be given.  Additionally, consideration of parents’ responses to their 
child’s condition and associated medical and surgical treatment will be offered.  From these data 
we can evaluate what is known about several influences that significantly impact behavioral 
development in children and adolescents with DSD, as well as suggest new areas of study to 
improve outcomes for affected children and their family members who care for them. 
 
 
I-10 The Constraints of DSD Applications in Resource Poor Countries 
Syed Jamal Raza, National Institute of Child Health, Karachi, Pakistan 
 
Islamic Republic of Pakistan is situated in South East Asia is the 7th most populated country in the 
world. With only three paediatric endocrinologist and twenty adult endocrinologist for an 
approximate population of over 180 million, facilities for DSD are scarce and non-existent. In a few 
major cities where facilities are present they are extremely expensive and are out of reach for the 
general population. Various concerns and constraints have been identified during our 15 year 
experience of treating DSD patients. These range from religious, cultural, social, and financial to 
limited facilities available for investigations and treatment. DSD patients and their families face 
unprecedented discrimination from society which begins right after the birth of the child. Being a 
male dominated society blame often falls solely on the woman. Due to all these issues a unique 
culture of “Hijra” has automatically developed in society as people learn to cope with the 
untreated psychological trauma of DSD. These Hijras were often employed as late as the Mughal 
Emperors as they were able to move freely among segregated sections for females and males. 
Until last year they for centuries have never been given full civil rights. 
We will be discussing these constraints with a case based approach so that this dilemma can be 
clearly understood as DSD practice in Pakistan consists of making the most of what inadequate 
facilities we have available. The impact from international partnerships is immense as much 
needed genetic screening is made available free of charge to our patients. 
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I-11 Strengths and weaknesses of current research and future directions 
David E. Sandberg, University of Michigan Medical School, Ann Arbor, MI, USA 
 
Background 
Persons born with disorders of sex development (DSD) have presented researchers with 
opportunities to examine the influence of biological (ie, genetic and hormonal) factors on the 
process of psychosexual differentiation (gender identity, gender role and sexual orientation). 
Research findings, commonly published in medical journals, are potentially misleading and 
confusing to health care providers, affected persons, and families regarding their import for 
clinical management (eg, significance of gender-atypical behavior). Further, relatively little 
consideration has been given to social contextual factors that mediate (eg, physical appearance, 
body-image, homophobia) or moderate (eg, family ethnic or religious background and associated 
beliefs) the effect of biologic factors on developmental outcomes. An overemphasis on biological 
predictors of gender-related outcomes may also have been associated with a scarcity of studies 
investigating condition-specific factors (eg, stigma and associated secrecy) and clinical 
management practices (eg, genital surgery, their complications and repeated genital 
examinations) that conceivably influence gender and other health-related quality of life outcomes. 
Finally, the majority of studies have been quantitative, employing standardized measures to assess 
behavior in predetermined domains. Relatively few studies employed qualitative or mixed 
methods. 
  
Aim 
Propose the hypothesis: developmental trajectories in chronic pediatric conditions (ie health-
related quality of life), including DSD, are influenced as much by the psychosocial environment, 
supports, and organization of health care delivery as by the specific nature of the person’s medical 
condition.  
 
Discussion 
Adopting a “noncategorical” approach to DSD clinical care and outcomes research that takes 
mediating and moderating factors into account will accelerate discovery and improvements in care 
by opening this set of rare conditions to advances in other areas of pediatric and behavioral health 
care. 
 
 
I-12 Making sense of the genetic information 
Ken McElreavey, Human Developmental Genetics, Institut Pasteur, France 
 
Next generation sequencing technologies are dramatically changing biomedical research and 
patient diagnosis. The plummeting costs of exome and whole genome sequencing as well as 
robust experimental and computational protocols means that this technology is becoming 
available to most laboratories. However, the identification of disease-causing mutations in 
individuals with DSD and DSD-related phenotypes such as cryptorchidism and hypospadias will be 
challenging.  The following factors needs to be considered for an accurate genotype to phenotype 
correlation 
 
(i) Defining the phenotype 
The availability of the genomic sequence of an individual with DSD highlights the need for a highly 
accurate clinical description of the phenotype using a standardized precise protocol. For some DSD 
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phenotypes, such as gonadal dysgenesis or ovotesticular DSD, this is relatively straightforward but 
it is less so with cases of undervirilised 46,XY DSD and especially those who are raised as boys. 
These cases are often investigated to a variable extent and for the majority the aetiology remains 
unclear. The situation with non-syndromic hypospadias is even more complicated. Hypospadias is 
considered multifactorial with contributing genetic and environmental factors. Familial clustering 
without a clear inheritance pattern has been reported suggesting a genetic component, however 
genetic association studies have for the most part failed to identify the pathogenic gene. Rare 
mutations have been identified in association with hypospadias and are mainly associated with 
severe posterior forms rather than the distal or glandular forms. This suggests that environmental 
factors may predominate in the milder glandular forms of hypospadias perhaps in genetically 
susceptible individuals. If we are to precisely determine the genetic basis of these phenotypes we 
need to accurately record subtle differences in clinical measurements including those obtained 
through non-conventional approaches such as metabolomics.  
 
(ii) Genetic heterogeneity 
Genetic heterogeneity refers to the degree to which a single phenotype/disease is caused by 
multiple loci amongst different patients. The degree to which DSD displays extensive genetic 
heterogeneity is unknown but could be extensive. For example, the androgen receptor has been 
reported to interact with hundreds of cofactors. There are many online tools available that help to 
interpret genetic data such as defining gene ontology and pathway analyses and these may help to 
link the disease variant with the phenotype. However, where a considerable number of novel 
genes are involved a large numbers of subjects may be required to attain sufficient power to 
identify variants causing and modulating the expressivity of the phenotype. Increasing the size of 
the patient cohort will increase the power to discover disease-causing variants. This is particularly 
important for DSD, where familial cases that could help to link the phenotype with the genotype 
are rare.  
 
(iii) Functional studies 
The definition of the patient phenome together with extensive genetic and other -omic datasets 
must be supplemented by functional in vitro, ex-vivo and in vivo models to dissect the molecular 
pathways underlying the pathology and giving not only diagnosis to all patients with DSD but also 
potential personalised therapies.  
If we are truly to make sense of the genetic data, it will require a strong multi-center and 
multidisciplinary approach. Combining the expertise of international clinical and research centers 
through initiatives such as I-DSD is essential if we are to understand the genetic basis of DSD.    
 
 
I-13 Grappling with steroid metabolomics 
Nils Krone, Centre for Endocrinology, Diabetes and Metabolism, School for Clinical and 
Experimental Medicine, University of Birmingham, UK 
 
Disorders of steroidogenesis have been primarily studied through quantification of selected 
analytes by immunoassays. Structural similarity of steroids compromise specificity of 
immunoassays by crossreactivity, and immunoassays are notoriously inexact in low concentration 
ranges as seen in paediatrics. During recent years laboratory investigations of patients suffering 
from potential endocrine conditions has become more accurate. High-performance liquid 
chromatography/ tandem mass spectrometry (LC-MS/MS) is the most successful approach to 
improve specificity problems inherent in many immunoassays and has become the method of 
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choice for clinical steroid analysis. LC-MS/MS is increasingly replacing immunobased techniques 
because of its high sensitivity, greater specificity, high reproducibility and ability to analyse 
multiple steroids from small sample volumes simultaneously. LC-MS/MS is a highly valuable 
second-tier test in CAH newborn screening and is enhancing diagnostic capabilities of routine 
testing particularly when steroid profiles are available. However, LC-MS/MS is of limited use in 
defining novel metabolomes. Gas chromatography mass spectrometry (GC/MS), in contrast, is 
unsuitable to rapid high sensitivity analysis of specific compounds, but is the most powerful 
discovery tool for defining steroidobolomes. GC/MS has defined several metabolomes with the 
most recent being apparent cortisone reductase deficiency and P450 oxidoreductase deficiency. 
Almost all steroidogenic conditions are defined by the absolute concentration of steroid 
metabolites, many are diagnosed between ratios of substrate metabolite to product metabolite of 
enzymatic reactions. Such methods are sensitive enough to distinguish between the differential 
impairment of 17, 20 lyase caused by mutations in either CYP17A1, POR or cytochrome B5. A 
particular benefit of GC/MS is its non-selective nature; a scanned run will contain every steroid 
excreted, providing an integrated metabolome. The analysis of such “undefined” metabolomes 
using i.e. biocomputational analysis by supervised machine learning tools provides the opportunity 
for identification of novel metabolomes and characterisation of novel steroidogenic disorders 
causing DSD. 
 
 
I-14 The Future of Rare Disease Registries 
Domenica Taruscio, National Centre for Rare Diseases, Istituto Superiore di Sanità,  Rome, Italy.  
 
Rare diseases (RD) have become in the last years a hot topic of public health all over the world. In 
Europe, the EU Council Recommendation on RD (2009) stimulated the development of national 
plans or strategies in the EU Member States, a wide array of coherent actions to improve care of 
RD patients, which included international cooperation and the development of registries. More 
recently, the EU Directive on Cross-Border Health Care (2011) identified RD as the paradigmatic 
topic to start development of cooperation and of European Reference Networks, through which 
clinical data are shared. At the same time, an International research consortium (IRDiRC) has been 
established for research into RD and development of new orphan drugs. This initiative, initiated by 
United States and EU, has been joined individually by Japan, Canada and several EU Countries; 
further countries are negotiating to join it. All these initiatives have triggered a number of projects, 
which, with different but partially overlapping methods and scopes, promote data sharing and 
interoperability: EPIRARE, PARENT, RD-Connect and EUROCARE. All these activities change the 
perspective of RD registries and will mark a transition from spontaneous registries, often resulting 
from specific research interests and with difficult sustainability, to a more coordinated system of 
registries. This system should assures a number of outputs of use to the different funding 
stakeholders, and provides tools, resources and a quality assurance environment to the 
participating registries without hindering the development of research studies. It is expected that 
such transition will also result in higher confidence of patients and in higher numbers of registered 
patients. The main features of this system will be discussed. 
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I-15 The Genetics of Gonad Development  
Andrew Sinclair, Murdoch Children’s Research Institute and Dept. of Pediatrics, The University of 
Melbourne, Royal Children’s Hospital, Melbourne, Australia 
 
Disorders of sex development (DSD), ranging in severity from genital abnormalities to complete 
sex reversal, represent a major clinical concern. The cause of these disorders is most often a 
disruption of the genetic programs that regulate development of testes or ovaries. Alterations in 
the key testis genes SRY, SOX9, FGF9 and ovary genes such as RSPO1, WNT4, β-catenin, FOXL2 are 
associated with DSD. In addition, NR5A1 affects multiple points in the gonad and steroidogenic 
pathway and defects in it are associated with many forms of DSD. Despite this knowledge in many 
cases of DSD the causative mutations are not known. We have identified copy number changes 
identified rearrangements that affected known and novel gonad genes. Known genes affected 
included: a deletion in the upstream regulatory region of the SOX9 gene in a 46,XY DSD individual. 
Amongst other potentially causative findings were rearrangements affecting the X-linked SOX3 
gene in three unrelated 46,XX DSD patients. This is the first evidence in humans that SOX3 may be 
functionally interchangeable with the testis gene SRY. We were also able to demonstrate that 
mutations in the MAP3K1 gene cause testis failure. This suggests a new signaling transduction 
pathway is involved in testis determination. These analyses give new insights into the molecular 
genetic pathways underlying human gonad development and dysfunction. Our data have 
generated a number of new candidate genes for future diagnostic screening. 
 
 
I-16 The Fate of the Gonad in DSD 
Leendert Looijenga, Erasmus-MC, Rotterdam, The Netherlands 
 
Various risk factors have been identified for development of so-called type II malignant gonadal 
germ cell tumors (GCC), i.e., seminomatous and nonseminomatous cancers. These include 
cryptorchidism, infertility, a previous GCC, familial predisposition, as well as specific forms of DSD. 
These latter include patients with gonadal dysgenesis and hypovirilization combined with presence 
of a specific part of the Y chromosome, known as GBY (GonadoBlastoma on the Y chromosome). 
TSPY (Testis Specific Protein on the Y chromosome) is one of the likely candidates to be involved.  
The precursor lesion of GCC can be either Carcinoma In Situ (CIS) of the testis, or GonadoBlastoma 
(GB) of the dysgenetic gonad. The germ cells affected are embryonic in origin and characteristically 
express markers like OCT3/4, SOX17, c-KIT etc. The supportive cells are Sertoli cells, recognized by 
SOX9, in CIS and Granulosa cells, recognized by FOXL2, in GB. Dependent on the level of 
“Testicularization”, either CIS or GB, or a mixture of both precursor lesions can be found. SCF, also 
known as KITLG, is reported to be informative to distinguish the earliest (i.e., pre-) malignant germ 
cells from embryonic germ cells showing only a delayed pattern of maturation. This is suggested to 
be related to a temporarily autocrine loop, which is of specific interest because of the recent 
linkage found to Single Nucleotide Polymorphisms (SNPs), related to genes involved in early 
gonadal development, including KITLG. Based on the current knowledge of normal gonadal 
development as well as the pathogenesis of GCC, a clinical decision tree is presented informative 
to identify and monitor DSD patients for their risk to develop this kind of cancer. Clinical 
implementation of such a proposal will prevent unnecessary treatment (including gonadectomy) 
on the one hand, and underdiagnosis on the other.    
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I-17 Imaging the Gonad 
MA Hall-Craggs, University College London, UK 
 
Imaging of retained gonads is performed for a number of reasons 
1. To identify their presence or absence 
2. To monitor changes that suggest malignant transformation 
3. For image guided biopsy 
The most common gonads imaged are retained testes in XY DSDs. The methods of choice for 
imaging are ultrasound and MRI. Ionising radiation (such as CT) should be avoided for imaging any 
gonad. Ultrasound is a useful tool for imaging gonads sited in the inguinal canals, but is less good 
for visualizing pelvic and abdominal gonads where they may be obscured by bowel loops.   
Retained testes in the presence of a DSD have abnormal appearances compared with ‘normal’ 
testes. In a study we performed reviewing the MR imaging and histology of patients over 16 years 
with CAIS and retained gonads, we found that the testes were smaller than in the normal male, 
and over 50% contained low signal nodules. These corresponded histologically with Sertoli 
adenomas. The majority of testes show small paratesticular cysts. In our series the small number 
of testes with premalignant change could not be identified on MRI.  
There are currently no data to suggest that imaging can be either sensitive of specific for 
identifying malignant changes. The rate of progression from non-malignant, to pre-malignant to 
invasive tumour is not known for certain and therefore the length between imaging examinations 
is currently arbitrary. Newer tools such as cell tracking techniques might hold potential for the 
future.  
 
 
I-18 The practical management of an adult at risk of gonadal tumourigenesis 
Gerard Conway, University College London Hospitals, UK 
 
Care of adults with DSD poses many challenges not least because most information in the field is 
based entirely based on paediatric experience. There is little guidance for making an accurate 
diagnosis in adults with a female phenotype who might present with amenorrhoea bypassing 
paediatric services or who have had a previous diagnostic workup that cannot be verified.   
Furthermore, the group of women often over that age of 25 for whom paediatric care might not 
have been transparent in terms of accurate diagnostic information, may have a legacy if 
psychological issues that hinder engagement with medical services.   
 
In the surgical field, adults with DSD have to cope with variable outcomes from genital surgery 
that require ongoing care.  Medical aspects of an adult DSD service include optimisation and an 
individual approach to sex steroid replacement as well as long-term health surveillance such as 
monitoring bone density and cardiovascular risk.  
 
In a world where individuals attending an adult DSD service are often highly informed experts in 
the field, the role of medical care is often to guide on safety aspects and accept that the evidence 
base from which conventional practice has developed is questionable.  One example of this area is 
the practice of gonadectomy for women with complete androgen insensitivity syndrome for whom 
there is very little data in adults but at the same time a practical approach has to be developed to 
follow individual expectations. 
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Abstracts - Oral Communications 
 
O-01 Caroline Sanders 
Young women with DSD their reported experiences of clinical conversations with healthcare 
professionals. 
Sanders, C & Carter, B 
UCLan, CNRU and Alder Hey Children's NHS FT 
 
Background: Young women’s experiences of learning about their DSD and their interactions with 
health care professional are under reported. Aim: To explore young women’s expectations of and 
experiences of clinical conversations. Methods: Young women in the UK were interviewed or 
completed a diary (2011-12) focusing on their experiences of clinical conversations with a range of 
healthcare professionals. An IPA approach was used to analyse these data. Results: Thirteen young 
women (43%, n=13/30, 14-19 years, mean 16.8 years) with a range of DSD conditions participated. 
The theme ‘communication with professionals; impact on identity and autonomy’ is reported here. 
The young women experienced tensions in communication arising from the unpredictability of 
which professional they saw and what information their parents had shared previously. They 
needed more information about their own clinical history and their DSD trajectory to facilitate 
decision-making. Gathering information was problematic; they felt that professionals’ assumed 
that parents had the knowledge, capacity, capability and willingness to share complex DSD 
information. However, parental information was perceived to be subjective and edited. Good 
communication skills, respect, privacy and opportunity were seen to be essential to successful 
engagement and participation in clinical conversations. Discussion: Professionals need to provide 
objective information so that young women can fill in the gaps in their knowledge about 
themselves thus challenging the insecurity brought about by uncertainty or ignorance. Young 
women believed knowing, trusting and building confidence over a period of time with health 
professionals were fundamental to supporting effective clinical conversations. Young women 
often felt their local health provider should manage their everyday health needs while specialist 
services would be best suited to helping them understand their DSD. Conclusion: In order to 
overcome the asymmetry of knowledge within clinical conversations between professionals, 
parents and young people ways to improve communication share knowledge and support 
participation are needed. 
 
 
O-02 Inas Mazen 
Clinical and genetic characterization of 232 Egyptian DSD patients 
Mazen, Inas 
National Research Centre , Cairo, Egypt 
 
Background Disorders of sex development (DSD) comprise a heterogeneous group of heritable 
abnormalities of sexual determination and differentiation. In Egypt the incidence of DSD is 1 in 
5 ,000 , due to the high rate of consanguinity Aim of study This study is among a project funded by 
NRC aimed at proper classification of DSD patients to establish a precise diagnosis to offer a better 
genetic counseling . Methods Karyotyping , FISH in blood and gonads and sequencing of SRY , AR, 
HSD17B3, SRD5A2 and SF1genes. Results The study included 232 patients with variable presenting 
features, referred to the Human genetics clinic during the period 2011-2012. Abnormal karyotypes 
were detected among 129 patients and represented different arrays of chromosomal anomalies. 
Numerical sex chromosomal abnormalities included 45,X karyotype, occurring in pure or mosaic 
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forms (51 patients ), 47,XXY (53 patients), 47,XXX (4 patients) and 49,XXXXY (one patient). 
Structural sex chromosomal abnormalities were seen in 36 patients, either in a pure form or 
associated with 45,X mosaicism. They included iso (Xq) abnormality (21 patients), isodicentric Y 
chromosomes (9 patients), ring X (3 patients), X;Y translocation, , add (Xq) and del (Xp) (one 
patient each). XX testicular DSD was found in 4 patients, one of them presented with Down 
syndrome. Autosomal abnormalities were detected in 6 patients in association with other 
congenital anomalies. Molecular analysis was done for 45 patients with 46,XY DSD. Nine patients 
showed different mutations in HSD17B3 gene, including a novel one. Another novel mutation of 
AR gene was detected in a large family. SF1 mutation was found in 3 patients and G34 R mutation 
was found in SRD5A2 gene, confirming the gene founder effect. Conclusion This extensive study 
added more informative clinical, cytogenetic and molecular data and reflected the heterogeneity 
of Egyptian DSD patients. 
 
 
O-03 Annastasia Ediati 
Gender outcome and sexual functioning in Indonesian patients with a disorder of sex development 
(DSD) 
A. Ediati 1,2,3, A.Z. Juniarto 2,3, E. Birnie 4, S.L.S. Drop 5, S.M.H. Faradz 2,3, A.B. Dessens 5 
1Faculty of Psychology, Diponegoro University, Semarang, Indonesia, 2Center for Biomedical 
Research (CEBIOR), Faculty of Medicine, Diponegoro University (FMDU), Semarang Indonesia, 
3Sexual Adjustment Team, FMDU-Dr Kariadi Hospital, Semarang, Indonesia, 4Institute of Health 
Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands, 
5Department of Paediatrics, Division of Endocrinology, Erasmus MC-University Medical Centre, 
Rotterdam, the Netherlands 
 
Background: In Indonesia, comprehensive treatment for individuals with DSD became available 
recently. Consequently, many affected individuals had been living untreated or received treatment 
late in life and have been raised in an ambiguous body and gender. Objective: To investigate 
gender identity, gender role behaviour, and sexual functioning in patients with DSD. Patients were 
compared to healthy controls matched for gender, age, and socio-economic background. 
Methods: Subjects: Cross sectional study comparing 116 patients aged 6-41 years and 116 healthy 
matched control subjects. Materials: Gender identity and gender role behaviour was measured 
using Indonesian versions of GII and GIQC for children; Activities and Gender Questionnaires for 
adolescents/adults. Sexual functioning was measured only in adults using Indonesian versions of 
FSFI, FSDS-R and MSHQ. Statistical analysis: Principal Component Analysis and Cronbach’s alpha 
were applied in measuring construct validity and internal consistency. Differences between 
patients and controls were compared using Mann-Whitney U-test. Results: Social gender role 
change was reported in 20/116 (17%) patients: 4/60 (7%) children; 2/23 (9%) adolescents and 
14/33 (42%) adults. All changed from female to male. Patients living as girls reported more often 
long-term gender-related problems (i.e. affective gender confusion and cross-gender role 
behaviour) than their matched controls did. 14/18 (78%) adult women and 7/21 (33%) adult men 
never had sexual/romantic relationships. Taboo, fear of ostracism, and infertility were the 
reported as main reasons for delay or refusal in entering a romantic relationship. Women 
experienced great distress due to infertility. Discussion: Particularly women are disadvantaged 
since gender identity problems largely occur among patients assigned female at birth, and 
infertility causes distress in a collective-driven society that expects procreation. Conclusion: Many 
untreated or late-treated patients experience gender identity problems. Counselling and 
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education on DSD is prerequisite to promote social acceptance of DSD. Follow-up is needed to 
compare late-treated with early-treated patients. 
 
 
O-04 Nina Callens 
Phalloplasty for men with DSD and micropenis 
N. Callens (1), G. De Cuypere (2), E. Van Hoecke (3) , G. T’Sjoen (2,4) , S. Monstrey (5) ,P. Hoebeke 
(6), and M. Cools (1) 
(1)Ghent University and University Hospital Ghent , Department of Pediatric Endocrinology , De 
Pintelaan 185, 9000 Ghent, Belgium (2) Ghent University and University Hospital Ghent , 
Department of Sexology and Gender Problems , De Pintelaan 185, 9000 Ghent, Belgium (3)Ghent 
University and University Hospital Ghent, Department of Pediatric Psychology , De Pintelaan 185, 
9000 Ghent, Belgium, 4 University Hospital Ghent, Department of Endocrinology, De Pintelaan 185, 
9000 Ghent, Belgium, 5 University Hospital Ghent, Department of Plastic Surgery, De Pintelaan 
185, 9000 Ghent, Belgium, 6 Ghent University and University Hospital Ghent, Department of 
Urology , De Pintelaan 185, 9000 Ghent, Belgium 
 
Background: The term ‘micropenis’ encompasses a range of congenital and acquired conditions 
resulting in an abnormally short penis. Small penis size may persist into adulthood, becoming a 
major cause of dissatisfaction. Can phalloplasty, generally applied in the context of transgender 
surgery, be a valuable treatment for men with micropenis? Objective: We aimed to assess long-
term (> 1 year post surgery) sexual Quality of Life (QoL) outcomes after phalloplasty in 46, XY male 
patients with penile insufficiency. Methods: Ten men (20 - 43 years) received phalloplasty (8 with 
radial forearm free flap and 2 with anterolateral thigh flap) between March 2004 and June 2011 
(follow-up, 14 to 92 months). All but one had erectile implant surgery approximately 1 year after 
phallic reconstruction. All patients received psychological counseling before and after surgery. 
Sexual QoL was assessed with a semi-structured interview. Results: All men suffered from their 
condition before surgery, with low self-esteem and sexual dysfunction. After phalloplasty, all men 
reported a boost in self-confidence, and experienced orgasm with ejaculation. However, 60% was 
still afraid of partner reactions and sexual rejection or had trouble with the use of the erection 
prosthesis, making sexual enjoyment not obvious. Neophallus sensitivity was said to be poor and 
scars at the donor site were important. Five men developed urinary complications (stricture or 
fistula) and in one man the erectile implant had to be removed because of an aneurysmal swelling. 
Nevertheless, all indicated they would choose again for phalloplasty if necessary. Discussion: 
Phalloplasty opens new horizons for the treatment of 46, XY DSD patients with penile deficiency, 
but limitations of the technique should be emphasized prior to surgery. Psychological support 
should be an integral part of the management in alleviating the distress and impairment of sexual 
QoL. Publication of series with large numbers and longer follow-up is needed. 
 
 
O-05 Gabriele Jergl-Corkin 
Management of children with CAH. Time of correction and operation methods of virilized genitales 
and longterm outcome. 
G. Jergl-Corkin; C. Leriche 
Deptment of Pediatric Surgery, CA Dr. C. Leriche, University Hospital Ulm, General Surgery, Head: 
Prof. Dr. D. Henne-Bruns 
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We would like to present the management of children with CAH at the University Hospital Ulm, 
Germany. The timing of the correction of virilised genitalia is still discussed controversially. At our 
center, children and parents are investigated and counseled in a special outpatient clinic for DSD 
by pediatric endocrinologists, pediatric psychologists, social workers, geneticists and pediatric 
surgeons, who are specialized in this field. It is mandatory to discuss all aspects concerning the 
timing and method of the operation extensively and individually with every family. All patients are 
regularly followed up. The medical transition to the adult specialists is planned at the end of 
puberty. Having learned over the years from the psychological and sexual problems CAH patients 
can encounter we have optimized our technique and adapted it to the individual patient. We will 
briefly present our operation methods. In treating adult CAH patients, who were previously 
operated with other techniques/other centers and who were unhappy of the insufficient cosmetic 
and functional results, we gained further experience and developed own techniques for revisions. 
Over a 27 year period our specialized pediatric surgeon has operated over 600 children with CAH, 
performing clitoris reductions, vaginoplasties and reconstructions of the labia. In this follow-up 
study we present the outcome of 126 patients aged 17-25 years. All of them had surgical 
corrections as an infant. In conclusion, the best results are obtained when the correction of 
virilized genitalia is performed in infancy and not in puberty. There are less psychological problems. 
All patients have to have a good follow up and should be told the whole truth about their 
malformation. If that is the case puberty is no greater problem as in other girls. The mayor goal in 
treatment of CAH patients is a happy child with a normal possibility of sexual development. 
 
 
O-06 Patricia Y. Fechner 
A Multicenter, Interdisciplinary Disorder of Sex Development Registry 
P.Y. Fechner, E. Vilain, and D.E. Sandberg 
Seattle Children’s Hospital; University of California, Los Angeles; University of Michigan 
 
Background: The care of individuals with Disorders of Sex Development (DSD) requires evidence-
based clinical practice guidelines which have been lacking due to the low incidence of many DSD. 
Objectives: Using an interdisciplinary team approach, the DSD-Translational Research Network 
(DSD-TRN) seeks to inform evidence-based care through standardizing diagnostic and treatment 
protocols. With reduced variation in clinical practice and enhanced patient and family healthcare-
related experiences improved quality of life outcomes are expected. Methods: The DSD-TRN 
consists of four medical centers (Seattle Children’s Hospital; University of California, Los Angeles; 
University of California, San Francisco; University of Michigan) and a non-governmental health 
care organization with representation from the major DSD advocacy organizations (Accord 
Alliance). The governance structure includes a leadership group and four workgroups, each with 
specialty and network site representation: Anatomy/Surgery, Endocrinology, Genetics, and 
Psychosocial. Workgroups have defined data elements to be included in the comprehensive 
registry that track the process of diagnosis and ongoing clinical management in all domains. 
Results: Data collection forms have been prepared and are being integrated into ongoing patient 
care as each center receives institutional review board approval. The goal is to populate the 
Registry with 800 participants. Discussion: Although consensus for many assessments and 
procedures was established (eg, uniform terminology, exams and laboratory studies performed), a 
decision was made to have the Registry capture variability where consensus remained elusive. 
Analysis of registry data will focus on the associations between variability in clinical practices and a 
range of outcomes. Conclusion: Through the process of defining data elements for a registry, we 
have begun the process of standardizing care for persons with DSD. The ultimate goal of this effort 
7th-9th June 2013, Glasgow, UK 
26 
 
is expanded discovery for this set of rare disorders and establishment of evidence-based best 
practices. 
 
 
O-07 Kathryn Cox 
Range and Patterns of Associated Conditions in Disorders of Sex Development: Findings from the I-
DSD Registry 
Kathryn Cox1, Jillian Bryce1, Jipu Jiang1, Martina Rodie1, Richard Sinnott2, Mona Alkhawari3, 
Wiebke Arlt4, Antonio Balsamo5, Silvano Bertelloni6, Martine Cools7, Feyza Darendeliler8, 
Stenvert L Drop9, Mona Ellaithi10, Tulay Guran11, Sven Olaf Hiort12, Paul-Martin Holterhus13, 
Ieuan Arwel Hughes14, Lidka Lisa15,  Yves Morel16 Olle Soder17 
(1)University of Glasgow, (2)University of Melbourne, (3)Al- Amiri Hospital, Kuwait, (4)Sch of Clin & 
Experiment Med, Univ of Birmingham, Birmingham, United Kingdom, (5)University of Bologna, 
(6)University of Pisa, (7)Dept of Pediatrics, Univ Hosp Ghent, Ghent, Belgium, (8)Department of 
Pediatrics, Istanbul Faculty of Medicine, Istanbul, Turkey, (9)Div Endo, Sophia Childrens Hosp, 
Rotterdam, Netherlands, (10)University of Khartoum, Sudan, (11)Marmara University Hospital, 
(12)Pediatrics, Univ of Luebeck, Luebeck, Germany, (13)Camous Kiel, Univ Hosp Schleswig-Holstein, 
Kiel, Germany, (14)Dept of Paeds, Univ of Cambridge Sch Clin Med, Cambridge, United Kingdom, 
(15) Children Clinic, Med Schl Charles Univ, Prague, Czech Republic, (16) Hopital Debrousse, Lyon 
France, (17)Woman and Child Hlth/Ped Endo, Karolinska Inst, Stockholm, Sweden 
 
Background: Improved knowledge of the range of anomalies encountered in DSD may improve our 
understanding of the underlying aetiology. However, given the rarity of these conditions, thorough 
analysis of congenital anomalies in DSD has not previously been possible. Aims: To discover the 
frequency of associated conditions in DSD, and to identify patterns of anomalies within specific 
disorders. Methods: 1050 registered cases on the I-DSD Registry (UKCRN#12729), currently used 
by 20 clinical centres in 14 countries, were examined. 649(62%) had consent level to allow sharing 
suitable information. Case details were obtained from the Registry and where information was 
unclear the reporting clinician was contacted to obtain further information. Results: Of 649 cases, 
congenital anomalies occurred in 173(27%); 107(62%) cases had one anomaly and 66(38%) had 
two or more anomalies. Commonest anomalies included renal-35(20%), heart-32(18%), skeletal-
32(18%), short stature-30(17%), small for gestational age(SGA)-28(16%) and CNS-27(15%). Of the 
46XY, 46XX and 45X/46XY cases, anomalies were encountered in 113(25%), 31(26%), 19(45%), 
respectively. In complete androgen insensitivity syndrome(AIS), congenital anomalies were 
reported in 8 cases reported to have a mutation in the androgen receptor(AR) gene (ARmut+ve) 
(range of anomalies: renal, GI tract, heart, skeletal, skin) and in 1 case which was ARmut-ve (renal). 
Corresponding data for partial AIS: total 10 cases, 2 ARmut+ve, 3 ARmut-ve, 5 unknown. Of 89 
cases of non-specific 46XY DSD, associated anomalies were encountered in 43(48%). The range of 
anomalies included SGA-17(40%), heart-10(23%), CNS-8(19%), renal-7(16%), GI tract-6(14%), ENT-
5(12%), skeletal-5(12%), craniofacial-4(9%), short stature-4(9%), eyes-3(7%), respiratory-3(7%), 
skin-3(7%), adrenal-1(2%), haematological-1(2%), unidentified syndrome-1(2%). Conclusions: 
Associated congenital anomalies occur frequently in DSD, including in monogenic conditions such 
as AIS which are generally thought to solely affect sex development. These findings provide a 
direction for further study of genetic and environmental causes of DSD. 
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O-08 Katya De Groote 
Cardiovascular pathology in males and females with 45,X/46,XY mosaicism 
K. De Groote (1), D. De Wolf (1), J. De Schepper (2), M. Craen (2), D. Devos (3), M. Cools (2) 
Ghent University Hospital and Ghent University, Ghent, Belgium. (1) Department of Pediatrics, 
Division of Pediatric Cardiology, (2) Department of Pediatrics, Division of Pediatric Endocrinology, 
(3) Department of Radiology 
 
Background: The phenotype of 45,X/46,XY mosaicism is heterogeneous ranging from females with 
Turner syndrome (TS) to apparently normal males. Males with 45,X/46,XY frequently show 
stigmata typically associated with TS. We hypothesised that males with 45,X/46,XY have similar 
cardiovascular pathology as females with 45,X/46,XY. Objective: To investigate cardiovascular 
abnormalities in 45,X/46,XY males and to compare them with 45,X/46,XY females Methods: 
Patients with 45,X/46,XY mosaicism were selected from the Belgian Registry for Growth and 
Puberty problems and via the multidisciplinary clinic for disorders of sexual development. They 
underwent a complete cardiac examination with blood pressure measurement, ECG, 
echocardiography and MRI. Clinical features and external masculinisation score (EMS) were 
retrospectively collected from the medical files. Results: Eighteen patients were included: 8 raised 
as females (F) and 10 as males (M). Seven F had classic TS features with typical female external 
genitalia and short stature; one child with ambiguous genitalia at birth was raised F. Four M were 
born with typical male external genitalia (EMS 12/12). Four showed milder (EMS 8-10/12) and 2 
severe (EMS 5-6/12) degrees of undervirilisation. In the 45,X/46,XY M, phenotypical features 
associated with TS were frequent. A structural heart defect was diagnosed before inclusion in 1 F 
with coarctation and 1 M with spontaneously closed VSD. A bicuspid aortic valve was found in 8 
(3F, 5M). Dilation of the ascending aorta was present in 4 M and was severe in 2 young boys. QTc 
was prolonged in 3 F and 2 M. Conclusion: Males with 45,X/46,XY mosaicism, also those with 
normal external genitalia or mild undervirilisation, have similar cardiovascular pathology as 
45,X/46,XY females. Dilation of the ascending aorta can be important, also in males. We advise 
cardiac screening and life-long monitoring in all males with 45,X/46,XY mosaicism according to the 
existing guidelines for Turner syndrome. 
 
 
O-09 Annalisa Nicoletti 
Copy number determination of sex determining genes by MLPA analysis in a patients with 46,XY 
DSD. 
A.Nicoletti, A. Balsamo, S. Menabò, F. Baronio, G. Cangemi, L. Baldazzi. 
O.U. Pediatrics, Program of Pediatric Endocrinology, Department of Medical & Surgical Sciences, 
S.Orsola Malpighi Hospital & University of Bologna, Bologna, Italy 
 
Background. Gene dosage mechanism is the basis of action of sex determining genes, such as 
NR0B1, WNT4, SOX9 and NR5A1. In 46,XY DSD patients (in particular with complete/partial 
gonadal dysgenesis, GD) the analysis of copy number variation (CNV) of these genes is part of the 
diagnostic tests already with the screening of mutations in SRY gene, the major candidate for 
46,XY GD. Objective. We studied CNV of sex determining genes in a patient with 46,XY partial GD 
that was negative for point mutations in SRY gene. Methods. The CNV was determined by MLPA 
analysis using MRC Holland Kit P185, containing several probes for SRY, NR0B1, WNT4, SOX9 and 
NRA51 genes, in genomic DNA from peripheral blood. The data analysis was performed by 
Coffalyser software. Results and Discussion. We identified a duplication of NR0B1 gene, the 
candidate for the X-linked 46,XY GD. The first reports come from patients with Xp region 
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rearrangements and complex phenotype including sex reversal. A minimal common region of 160-
kb was determined containing the NR0B1 gene, and regulatory sequences at hundreds kb 
upstream of NR0B1 gene were also recently identified. Actually it is confirmed its role in sex 
determination as an anti-testis gene, but animal model show a more complex function of NR0B1 in 
both sex changing over time and finely regulated. The genotype-phenotype correlation is 
therefore not well delineated, the severity of phenotype range from reduced testicular size and 
impaired germinal epithelium development until complete sex reversal. This is the case of our 
patient, diagnosed at 4 yrs of age as 46,XY GD, presenting genital virilization at 10yrs, with 
hormonal finding of partial hypergonadotropic hypogonadism, then diagnosis was corrected in 
partial GD. Conclusion. These data confirm that the analysis of CNV in the NR0B1 gene locus must 
be recommended in the majority of 46,XY DSD cases. 
 
 
O-10 Zofia Kolesinska 
Temporal Changes In Sex Assignment Based On Data Gathered From The I-DSD Registry 
Z Kolesinska1, SF Ahmed Z2, J Bryce2, M Alkhawari3, W Arlt4, A Balsamo5, S Bertelloni6, P 
Chatelain7, M Cools8, F Darendeliler9, A Desloovere8, S Drop10, M Ellaithi11, T Guran12, O 
Hiort13, P-M Holterhus14, I Hughes15, K Lachlan16, L Lisa17, I Mazen18, A Nordenstrom19, M 
Rodie2, O Soder20, R Tadokoro-Cuccaro15, N Weintrob21, Y van der Zwan10, M Niedziela1. 
1Poznan University of Medical Sciences, Poznan, Poland. 2University of Glasgow, UK. 3 Al-Amiri 
Hospital, Kuwait. 4University of Birmingham, UK. 5University of Bologna, Italy. 6University of Pisa, 
Italy. 7Université Claude Bernard Lyon 1, France. 8Ghent University Hospital and Ghent University, 
Belgium. 9İstanbul University Faculty of Medicine, Turkey. 10Erasmus MC-Sophia, The Netherlands. 
11Ahfad University for Women, Sudan. 12Marmara University, Istanbul, Turkey. 13University-
Hospital Schleswig-Holstein, Lübeck, Germany. 14University-Hospital Schleswig-Holstein, Kiel, 
Germany. 15University of Cambridge, United Kingdom. 16University of Southampton,UK. 
17Institute of Endocrinology Prague, Czech Republic. 18National Research Center, Cairo, Egypt. 
19Karolinska University Hospital Huddinge, Stockholm, Sweden. 20Karolinska Institute & 
University Hospital, Stockholm, Sweden. 21Schneider Children’s Medical Center, Petah Tiqva, 
Israel 
 
Introduction: It is unclear whether the proportion of children with DSD who are assigned a male 
sex or a female sex has changed over time. Aim: The aim of the analysis was to determine whether 
the appearance of the external genitalia assessed by the initial external masculinisation score 
(EMS) influenced the choice of sex of rearing and whether this changed over time. Methods: The 
analysis was performed on the data gathered in I-DSD Registry until February 2013. We defined 
the initial external masculinisation score as the EMS assessed in the neonatal/infancy period or in 
older cases as the EMS before any intervention. The cases were divided according to year of birth 
into three groups: those born before 1990, from 1990 till 1999 and born after 1999. Results: In 
partial androgen insensitivity syndrome (total n=109) the number of cases of male sex assignment 
(n=78) as well as the proportion of such cases (from 1,38 to 5,29) increased over time. There was a 
significant difference in the initial EMS between the group raised as boys (median 6, range 2-11.5) 
and the group raised as girls (median 2, range 0-8) p=0,000000. This significant difference of the 
initial EMS between the two sexes was observed over time. However, there was no significant 
difference in the initial EMS over time in the group raised as girls or in the group raised as boys. In 
fact, the degree of overlap for the initial EMS between the two sexes increased with time. 
Discussion: These data clearly show that there are clear trends in sex assignment and that they 
have been influenced by factors other than the appearance of the external genitalia. There is a 
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need to explore the underlying reasons for these trends.  The project was possible due to the ESPE 
Visiting Fellowship awarded to ZK in September 2012. 
 
 
O-11 Rieko Tadokoro Cuccaro 
Mining a large DSD database: success and failures 
R. Tadokoro Cuccaro, R Khairi, H.Miles, T. Bunch, IA. Hughes 
University of Cambridge, Department of Paediatrics, United Kingdom 
 
Background The Cambridge DSD Database contains clinical, biochemical, histological and genetic 
information on patients with 46,XY DSD, currently totalling 1800 cases. Aim To review the data to 
identify diagnostic groups suitable now for research projects and other categories that fail this test 
but have the potential for rectifying by further investment in research. Methods Data were 
collated via a questionnaire completed by the referring clinician at the time of notification. 
Analysis provided accurate diagnoses in 3 categories: defects in testis determination, defects in 
androgen production and defects in androgen action. Genetic analysis was then targeted to 
sequence 5 genes: 17HSDB3, SRD5A2, AR, SRY, NR5A1. Results The following yield was obtained: 
17 beta HSD deficiency ( n=30), 5 alpha RD deficiency ( n=45), complete androgen insensitivity 
syndrome (CAIS) ( n=239), partial AIS (PAIS)( n=59), all proven by demonstrating pathogenic 
mutations. In the testis determination category (gonadal dysgenesis, n=73), SRY and NR5A1 
mutations were detected in 14 and 6 cases, respectively. A further 390 cases with a phenotype 
predominantly similar to PAIS or possibly partial gonadal dysgenesis remain incompletely 
characterised. Discussion A large database when mined using comprehensive information has 
successfully identified a large proportion of the causes of XY DSD. This provides an excellent 
resource for further studies such as outcome in adulthood, including effectiveness of hormone 
replacement and risks for germ cell tumours. Less successfully mined is a large, less well 
characterised group without a DSD cause which would be ripe for analysis by newer genetic 
techniques, when phenotypic data are better gathered. The DSD professional community across a 
range of disciplines is challenged to utilise such database resources for further studies. 
 
 
O-12 Birgit Köhler 
dsd-Life: Clinical European study on the long-term effects of hormonal and surgical therapy and 
psychological intervention in disorders of sex development (DSD) 
B. Köhler(1), W. Arlt(2), C. Bouvattier(3), P. Chatelain(4), H. Claahsen-van der Grinten (5), P. 
Cohen-Kettenis (6), A. Nordenström (7), C. Pienkowski (8), A. Richter-Unruh, J (9). Slowikowska-
Hilczer (10), C. Sultan (11), M. Szarras-Capnik (12), N. Reisch (13), U. Thyen (14), C. Wiesemann 
(15) 
1Institut für Experimentelle Pädiatrische Endocrinologie, Charité, Berlin, DE; 2Centre for 
Endocrinology, Diabetes and Metabolism, University of Birmingham, UK; 3Hôpital Bicêtre, 
Université Paris-Sud, FR; 4Hôpital Mère-Enfant de Lyon, Université Claude Bernard Lyon 1, FR ; 
5Radboud University Nijmegen Medical Center, NL; 6VU Medical Center Neuroscience Campus, 
Amsterdam, NL; 7Karolinska Institutet, Stockholm, S; 8Le Centre Hospitalier Universitaire de 
Toulouse, FR; 9Westfälische Wilhelms-Universität Münster, DE; 10Medical University of Lodz, PL; 
11Le Centre Hospitalier Universitaire Montpellier, FR; 12Children’s Memorial Health Institute, PL; 
13Ludwig-Maximilians- Universität, München, DE; 14Universität zu Lübeck, DE; 15Institut für Ethik 
und Geschichte der Medizin, Universitätsmedizin Goettingen, DE. 
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Background: Since the last two decades the genetic causes and the pathogenesis has been 
identified in many cases of DSD. However, clinical practice as decision on the sex of rearing, genital 
surgery and hormone therapies has a life-long impact on the affected persons and evaluation of 
long term outcome for clinical care is needed. Previous clinical outcome studies of DSD were 
limited by small patient numbers, different outcome measures and conglomerates of genetic 
defects. dsd-Life is a large and comprehensive outcome study integrating all medical and 
psychosocial issues to improve treatment and care of DSD. Objective: The aim of dsd-Life is 
improvement of clinical care of patients with DSD and development of European guidelines for 
clinical care of DSD. Moreover, dissemination of general knowledge about DSD to the public will 
be enhanced through the project. Methods: dsd-Life is a European study evaluating the long-term 
effects of hormonal and surgical therapy and psychological intervention in the different genetic 
entities of DSD: sex chromosome DSD (including Turner and Klinefelter syndrome), XY DSD and XX 
DSD. Different areas of high importance for long-term well-being will be evaluated: quality of life 
and psychological well-being, psychosexual development, metabolism and health. 
Patients’/parents’ view, ethics and cultural context will be considered. The dsd-Life project 
consortium consists of 15 European multidisciplinary DSD teams with longstanding experience in 
treatment and care of DSD. The consortium includes European DSD specialists in the fields of 
endocrinology, psychology, surgery, andrology, urology, gynaecology and ethics. dsd-Life 
communicates and collaborates closely with different national patient support groups. The 
recruitment of participants will start in October 2013 and will be performed by the study centres, 
associated hospitals, patient support groups and I-DSD. DSD-Life is a EU project (FP7/ 2007-2013). 
Funding 2012-2016. Coordination Dr. Birgit Köhler, Charité Berlin. 
 
 
O-13 Rod Mitchell 
Modeling Testicular Dysgenesis and Endocrine Disruption in the Human Fetal Testis 
Mitchell, Rod (1,2); Anderson, Richard (1); Kelnar, Christopher (2); Wallace, Hamish (2); Dean, 
Afshan (1), McKinnell, Chris (1); Sharpe, Richard (1). 
(1) Edinburgh University, MRC Centre for Reproductive Health, Edinburgh, United Kingdom (2) 
Edinburgh University, Department of Child Life and Health, Edinburgh, United Kingdom 
 
Background: Male reproductive disorders (cryptorchidism, hypospadias, testicular germ cell cancer, 
low sperm counts) comprise a ‘Testicular Dysgenesis Syndrome’ (TDS) with a common origin in 
fetal life. These abnormalities also occur in many of the Disorders of Sex Development (DSD). A 
variety of genetic and environmental (endocrine disruptors) factors are proposed to play a role in 
the aetiology of these disorders. Clear differences exist between rodents and humans in terms of 
testis development and dysgenesis and therefore human relevant models are required. Objective: 
1) Establish models of ex-situ human fetal testicular development to investigate seminiferous cord 
formation/disruption. 2) Determine the effects of proposed endocrine disruptors on the 
developing testis. Methods: We xenografted testis tissue/cells from fetal human (9-20 wks, n=21) 
or rat (e17.5, n=39), into nude mice. Morphological and immunohistochemical analysis was 
performed to investigate seminiferous cord formation/re-formation and cellular development. In 
addition, we treated host mice with a variety of proposed endocrine disruptors (paracetamol, 
phthalates or diethylstilboestrol) or vehicle. Testosterone production and the effect of exposure 
on testis development were determined. Results: Second trimester human fetal testis xenografts 
developed normally during the grafting period. Exposure to paracetamol during the grafting period 
resulted in a significant reduction in testosterone production, whilst exposure to di-n-butyl 
phthalate or diethylstilboestrol did not, in contrast to exposure in rats where all three result in a 
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reduction in testosterone. First trimester human fetal testis xenografts formed seminiferous cords 
during the grafting period, whilst xenografts of fetal rat isolated cell suspensions re-formed 
seminiferous cords with normal morphological appearance. Conclusions: We have demonstrated 
models of fetal testis development that can be invaluable for investigating seminiferous cord 
formation and its disruption in DSD/TDS. We also demonstrate the effects of exposure to 
proposed endocrine disruptors in the human fetal testis and highlight important differences from 
those seen in rodent studies. 
 
 
O-14 Capucine Hyon 
Refining the sex determining region located upstream from SOX9 gene. 
C. Hyon(1,2,3), R. Bhouri(1), S. Chantot-Bastaraud(1,2), A. Rouen(1), M. Peycelon(2,3), S. Rojo(4), K. 
McElreavey(4), JP. Siffroi(1,2,3), A. Bashamboo(4) 
(1) AP-HP, Groupe Hospitalier Universitaire de l'Est Parisien - Trousseau, Service de Génétique et 
Embryologie Médicales, Paris, 75012, France. (2) INSERM, UMR_S933, Paris, 75012, France. (3) 
Univ Pierre et Marie Curie, Paris, 75013, France. (4) Institut Pasteur, CNRS URA2578, Molecular 
Genetics 
 
Background: Most 46,XX testicular DSD cases carry the SRY gene, usually on one of their X 
chromosomes. In SRY-negative 46,XX testicular DSD rare genetic causes include mutations 
involving RSPO1 and WNT4 genes and rearrangements at the SOX9 and SOX3 genes. Recently, two 
families were reported with 46,XX testicular DSD carrying a duplication or a triplication of a region 
located about 600kb upstream from SOX9 (17q24). A further study defined a 78 kb region 
associated with either 46,XX DSD and 46,XY DSD when duplicated or deleted respectively. Aim: 
The aim of our study was to identify new regions involved in 46,XX SRY-negative DSD, and to 
define precise genotype-phenotype correlations. Methods: Two phenotypically normal brothers, 
initially referred for infertility, were shown to carry a 46,XX, SRY-negative, karyotype. They were 
then analyzed using the Illumina SNP array in order to identify potential deletions or duplications 
that could contribute to their phenotype. In addition, a testicular biopsy was obtained for each 
brother. Results: The two brothers carry a 77 kb duplication located 600 kb upstream from the 
SOX9 gene. Their duplication overlaps the critical region involved in SOX9 gene regulation in the 
developing gonad. The duplication was confirmed by independent qPCR analysis. Gonad histology 
revealed a normal seminiferous tubule organization. Ovarian tissue was not observed. Discussion: 
This duplication is the smallest one reported to date and defines the minimum region associated 
with DSD to a 64 kb interval, which includes three highly conserved regions. These latter could 
contain one ore more gonadal enhancers of SOX9 responsible for testicular differentiation when 
duplicated. Furthermore, the normal male external differentiation and the lack of Müllerian 
remnants suggest a functional endocrine testis secretion during the prenatal period. 
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O-15 Jolanta Slowikowska-Hilczer 
Preservation of Dysgenetic Gonads - Clinical Outcome 
J. Slowikowska-Hilczer1, M. Szarras-Czapnik2, J.K. Wolski3, K. Bajszczak1,2, L. Jakubowski4, E. 
Oszukowska1, K. Marchlewska1, R. Walczak-Jedrzejowska1, E. Filipiak1, K. Kula1 
1Dpt. of Andrology & Reproductive Endocrinology, Medical University of Lodz; 2Dpt.of 
Endocrinology and Diabetology, Children’s Memorial Health Institute, Warsaw; 3Urology-Oncology 
Dpt., Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw; 4Dpt.of Genetics, Institute CZMP, 
Lodz, Poland 
 
Aim of the study was to evaluate pubertal or adult patients with Y chromosome and ambiguous 
genitalia because of gonadal dysgenesis (GD). We evaluated 42 patients with GD, aged 15-46 years, 
with 46,XY (78.6% of cases), or mosaic karyotype. Serum levels of FSH, LH and testosterone were 
determined. Ultrasonography of gonads was performed. Preserved gonads were biopsied or 
removed. In total 83 gonads were histologically evaluated, including immunohistochemical 
reaction with monoclonal antibodies against placental like alkaline phosphatase (PLAP), a marker 
of neoplastic germ cells. Morphometry of testicular structures was achieved with the use of image 
analysis software. In all patients serum FSH level was increased above 10 IU/L (mean 63.7±38.3 
IU/L) and volume of gonads diminished (<10 ml). In 71.5% of patients serum testosterone level 
was below 8 nmol/l (mean 5.1±3.9 nmol/L), LH increased above 10 IU/L (22.1±12.7 IU/L) and they 
had clinical symptoms of hypogonadism. Germ cell neoplasia was found in 30.1% of gonads. 
Among them overt germ cell tumours were revealed in 10.8% of cases. In gonads with testicular 
structure intratubular germ cell neoplasia predominated (47.2%), while in the streak gonads 
gonadoblastoma (26.7%) was the most frequent. In one case spermatozoa were found, in one 
spermatogenesis was arrested at pachytene spermatocytes level and in another one at the level of 
spermatogonia. Sertoli cell only syndrome was found in 5 gonads with testicular structure (26.3%) 
and in one gonad seminiferous tubules were totally degenerated. Testicular structure revealed 
features of poor organogenesis: diminished tubular diameter, increased thickness of tubular 
membrane and increased intertubular spaces. In conclusion, dysgenetic gonads preserved until 
adulthood have poor growth and minimal probability to produce complete spermatogenesis. 
Moreover, they exhibit high risk of germ cell neoplasia. They have also poor hormonal activity, 
thus most of patients develop hypergonadotropic hypogonadism. 
 
 
O-16 Yvonne van der Zwan 
Chromatin profiling of germ cell cancer cell lines reveals differences in active enhancer states 
between Seminomas and Non-seminomas: a GENVIRONMENTAL connection? 
Yvonne van der Zwan1, 2*, Amanda Notini2*, Fernando Rossello3, Suzan de Boer2, Leendert 
Looijenga1#, Stefan White1# 
1. Department of Pathology, Erasmus MC – University Medical Center Rotterdam, Josephine 
Nefkens Institute, Rotterdam, the Netherlands 2. Centre for Reproduction and Development, 
Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia. 3. Centre 
for Cancer Research, Monash Institute of Medical Research, Monash University, Clayton, Victoria, 
Australia. 
 
Background Interplay between (epi)genetics and environment is involved in formation and 
maintenance of normal gonadal development. Primordial germ cells (PGCs)/gonocytes undergo 
specific epigenetic modifications. A disturbed micro-environment during this process might result 
in disturbed fertility and malignant transformation. Germ cell cancers (GCC) are the most common 
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cancer in young men, originating from PGCs/gonocytes, and are subdivided into seminomas (SE) 
and non-seminomas (NS). Somatic mutations are rare in GCC, therefore it is hypothesized that 
epigenetic disregulation might be involved. As such, investigation of histone modifications could 
be informative to elucidate the mechanisms involved in the formation of GCC, and might identify 
markers for risk stratification, diagnosis and prognosis. Aim Gain insight into the role of histone 
modifications in development of GCC. Methods We studied two well characterized GCC-cell lines, 
TCam-2 and NCCIT that are representative for SE and NS, respectively. Chromatin 
immunoprecipitation analysis was performed, using antibodies against three histone 
modifications; H3K4me1, H3k4me3 and H3K27ac. Libraries from the enriched DNA were prepared, 
and sequenced on the SOLiD 5500xl sequencer to generate genome-wide profiles. Results We 
identified a defined pattern of active regulatory regions within the genome, including promoters 
and enhancers. Initial analysis matched the classification of the cell lines; SOX17 was strongly 
enriched for H3K4me1 and H3K27ac in TCam-2 compared to NCCIT cells, whereas the opposite 
pattern was observed for SOX2. Detailed investigation of the epigenetic differences, in both the 
cell lines and primary GCC samples, is ongoing. Conclusion We generated a database of the 
epigenetic constitution of representative cell lines for the major variants of GCC, SE and NS. 
Extensive analyses, and confirmation of primary patient samples, is expected to give novel insights 
into the epigenetic differences between SE and NS, and may increase understanding of the 
maintenance of pluripotency characteristics of GCC, possibly linking genetic and environmental 
risk factors. 
 
 
O-17 Anu Bashamboo 
Exome sequencing reveals mutations in FOG-2 associated with 46,XY DSD 
Anu Bashamboo, Raja Brauner, Joelle Bignon-Topalovic, Sandra Rojo, Ken McElreavey 
AB, JBT, SR, KM: Unit of Human Developmental Genetics, Institut Pasteur, 25 Rue du Dr Roux, Paris 
75015, France RB:Université Paris Descartes and Fondation Ophtalmologique Adolphe de 
Rothschild, Paris, France 
 
Background. The underlying genetic aetiology in the majority of patients with 46,XY Disorders of 
Sex Development (DSD) is unknown. Aim(s)/Objective(s). The aim of the study was to identify 
novel causes of DSD using a whole exome sequencing approach. Methods. Following exome 
enrichment using the Agilent SureSelect V4 Exome Kit, exome sequencing was performed using 
the Illumina HiSeq 2000 platform at an average coverage of x50. Results and Discussion. We report 
two cases of 46,XY DSD associated with mutations in the Friend of GATA-2 (FOG2 or ZFPM2) gene. 
The first individual, who was raised as a girl, carried two missense mutations in FOG2. One was a 
heterozygous de novo mutation p.R260Q that is located in a highly conserved zinc finger motif. 
The other mutation, p.M554I was homozygous and inherited from each parent who are second 
degree cousins. The second individual presented with 46,XY complete gonadal dysgenesis and 
carried a heterozygous p.S402R mutation. This mutation was inherited from her mother and the 
family history indicated 46,XY DSD on the maternal side. In both cases ex-vivo functional assays 
indicated aberrant biological activity for the mutant proteins. These results highlight exome 
sequencing as a increasingly powerful and cost-effective technique to discover rare genetic 
variants associated with DSD. 
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O-18 Martina Rodie 
Sexual dimorphism of in vivo rodent brain chemistry using Magnetic Resonance Spectroscopy 
Rodie ME(1), Welsh M(2), Holmes W(3), Gallagher L(3), Mullin J(3), McMillan M(1), Macrae IM(3), 
Ahmed SF(1). 
(1)Department of Child Health, University of Glasgow, RHSC, G38SJ. (2)School of Life Sciences, 
University of Glasgow, Glasgow, G128QQ. (3)Glasgow Experimental MRI Centre, University of 
Glasgow, Garscube Campus, Glasgow. 
 
Background: By providing a non-invasive, functional insight, Magnetic Resonance Spectroscopy 
(MRS) has the potential to provide objective longitudinal data on mammalian brain development. 
Sexually dimorphic spectroscopy has been reported in humans but not in the rodent model. Aim: 
To assess the sexual dimorphism in rodent brain chemistry using in vivo MRS. Methods: Male and 
female Sprague Dawley rats were treated on postnatal days 1-5 with either 50mg/kg flutamide SC 
or corn oil and then scanned at the age of 6wks and 10wks using a 7TMRI scanner. Metabolites 
were expressed as a ratio to creatine and full width at half-maximum (FWHM) of the water peak 
was used as a marker of reliability. Results: Median weight in 6wk control males (MC6) and 
females (FC6), 6wk treated males (MT6) and females (FT6), 10wk control males (MC10) and 
females (FC10), 10wk treated males (MT10) and females (FT10) was 176g(range,137-230), 
127g(120-140), 177g(133-204), 131g(125-146), 302g(272-365), 205g(180-215), 289g(266-315) and 
196g(196-197) respectively. Anogenital distance(AGD) was reduced in MT6 and MT10 when 
compared with control males(p=0.003,p=0.019). Phallus length was reduced in MT10 (p=0.028). 
FWHM range was within the optimal range at 12-18Hz. MT6, MT10 and FC6 had higher myo-
inositol ratios when compared with control males(p=0.000,p=0.0821,p=0.037). In control males, 
there was a decrease from 6wks to 10wks in 3 metabolite ratios: GABA(p=0.011), 
glutamine(p=0.031) and glutamate(p=0.022). In control females there was also a decrease in 
glutamine and glutamate from 6wks to 10wks(p=0.033,p=0.016). Conclusions: Effects of neonatal 
androgen blockade are manifested in the male rat as undermasculinisation of the genitalia as well 
as a brain metabolite pattern which resembles that in the female rat . MRS is a reliable tool for 
studying the brain in maturing rats and may be a useful tool for studying the link between 
longitudinal changes in sex steroids and brain metabolism. 
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P-01 Angela Lucas-Herald 
The Outcome Of Prenatal Identification Of A Sex Chromosome Abnormality 
A. Lucas-Herald1, F. Cann2, L. Crawford3, C. Durajczyk4, R. McGowan2 and S.F. Ahmed1 
1) School of Medicine, University of Glasgow, Glasgow 2) Clinical Genetics Centre, North of 
Scotland Regional Genetics Service 3) Cytogenetics Department, West of Scotland Genetics 
Laboratory 4) Cytogenetics Department, North of Scotland Genetics Service 
 
Introduction: Prenatal diagnosis (PND) via amniocentesis or chorionic villus sampling may result in 
the identification of a sex chromosome abnormality, often as an incidental finding. Aims: To 
ascertain the incidence of sex chromosome abnormalities detected by prenatal diagnosis in the 
Grampian and the West of Scotland (WoS) regions and to determine the characteristics and 
outcomes of these cases. Methods: Retrospective review of all cases of prenatal diagnoses that 
revealed a sex chromosome abnormality between 2000 and 2012. Results: Over the period of 12 
years, 166 positive cases were identified. The indication for PND was an abnormal ultrasound scan 
in 95(57%), high-risk first trimester screening results in 31(19%), age related aneuploidy risk in 
24(14%), maternal anxiety in 9(5%) and a family history of a chromosomal abnormality in 7(4%). 
Of the 166 cases, 79(48%) cases were 45,X, 24(14%) were 47,XXY, 14(8%) were 48,XXX, 9(5%) were 
45,X/46,XX,, 8(5%) had a structurally abnormal X chromosome, 7(4%) were 45X/46XY, 6(4%) were 
48,XYY, 2(1%) were 46,XX/46XY and 17(11%) had other variations of sex chromosomes. Of the 166, 
73(44%) pregnancies were terminated and of these cases, 47(64%) had a karyotype of 45,X. An 
additional 7 pregnancies(4%) were associated with an intrauterine death and 5 of these were 45,X. 
Based on a combined birth rate of 40,000 births per year for these regions, it is estimated that 
there was one positive case for 3,500 births and approximately half of these led to a live birth. 
Conclusions: 1:7000 births are associated with a prenatally diagnosed sex chromosome 
abnormality. 45,X is the most commonly encountered abnormality. Given the rare incidence, there 
is a need to improve our understanding of the care of these cases during the pregnancy as well as 
afterwards. 
 
 
P-02 Angela Lucas-Herald 
Range Of Urinary Steroid Metabolite Ratios In Children Undergoing Investigation For Suspected 
Disorder Of Steroid Synthesis 
Angela Lucas-Herald (1), Martina Rodie (1), Neil Watson (3), Jane McNeilly (2), David Shapiro (3), 
Syed Faisal Ahmed (1) 
1 - Department of Child Health, University of Glasgow, RHSC, Glasgow 2 - Department of 
Biochemistry, Southern General Hospital, Glasgow 3 - Department of Biochemistry, Glasgow Royal 
Infirmary, Glasgow 
 
Background: Calculation of a urinary steroid metabolite ratio (uSMR) may be a useful method of 
improving diagnostic yield when investigating disorders of steroid hormone synthesis. Objective & 
Hypothesis: To investigate the range of uSMR in children with suspected disorders of steroid 
hormone synthesis. Population / Methods: Ten ratios were calculated on steroid metabolite data 
analysed by GC-MS in urine samples collected between 2008-2010 from 219 children who were 
undergoing investigations. To obtain reference data, urine samples were also analysed in 89 
children with no background of endocrine concerns and who had a urine sample collected at 
presentation to the hospital with an acute illness. Results: Of the 89 reference children, 36(40%) 
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were male and median age at time of the test was 3 yrs(range,1month-11yrs). Of the 219 
endocrine patients, 64(29%) were boys. In 129(59%) cases, a urine sample was collected to 
investigate early or exaggerated signs of adrenarche. Median age at test was 7.4yrs(1day-18yrs). 
Median and ranges of steroid ratios used in the diagnosis of 21-hydroxylase deficiency were 
calculated. Differences were noted in the reference ranges according to age and gender. 
Conclusions These novel data show that reference ranges for urinary steroid metabolite data need 
to be age matched. Most children with suspected disorders of steroid synthesis have a ratio which 
is within the reference range and the identification of outliers will lead to better targeting of 
genetic analyses. 
 
 
P-03 Erin Bergner 
News Coverage of Disorders of Sex Development, 1993-2012 
E. Bergner 
Vanderbilt University 
 
Background The news media is a powerful mechanism through which public understandings of 
medical conditions are created and shaped. Although news coverage can promote awareness 
about a condition and provide information about appropriate health care (Rowe et al. 2003), news 
media can also present unbalanced and often non-evidence-based claims about health topics, as 
seen in research on prostate cancer, depression, schizophrenia, and genetics (Goulden et al. 2011; 
McKenzie et al. 2007; Petersen 2001). Examining how disorders of sex development (DSD) is 
depicted in the news media offers insight into a range of clinical issues, including various social 
aspects of DSD diagnoses. Examining DSD through a lens of a social diagnosis (Brown et al. 2011) 
uncovers the interplay of broader social factors and individual conditions that affect health. 
Objectives In this analysis, I identify the range and quality of DSD-related issues discussed in the 
U.S. news media. I examine which clinical issues are given media coverage and what that coverage 
looks like, including how particular issues are framed. Methods Articles published between 1993-
2012 in four U.S. national newspapers (New York Times, Washington Post, Los Angeles Times, and 
USA Today) were collected using the keywords “intersex” and “disorder(s) of sex development,” 
yielding a sample of 106 news articles. Articles were coded for substantive content and themes, 
including the ways they describe DSD and the clinical issues they address. Results and Discussion 
DSD-related issues are receiving increasing attention from health advocates and medical 
professionals. Findings show that news media are also giving increased attention to DSD-related 
stories, particularly in the last five years. Many focused on runner Caster Semenya. My analysis 
shows that coverage often employs a biological frame, explaining the chromosomal or hormonal 
characteristics of DSD conditions. However, aspects of health care and treatment are sidelined. 
 
 
P-04 Karen Meadley 
Neovagina in patients with Mayer–Rokitansky–Küster–Hauser syndrome. 
K.Meadley(1) Co-authors: M.Deeny(2), J.Telfer(3) 
1West of Scotland Deanery, Princess Royal Maternity, Glasgow. 2University of Glasgow, Princess 
Royal Maternity Glasgow. 3Canniesburn Plastic Surgery Unit, Glasgow Royal infirmary 
 
Background: The diagnosis of an absent uterus and vagina is devastating in view of psychological, 
social and reproductive issues. The creation of a neovagina should be structural as well as 
functional to enable the woman have comfortable sexual intercourse. Aim: The aim is to discuss 
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the pros and cons of different methods available to create a neovagina, with special emphasis on 
the Mcindoe procedure. These include the low risk non-surgical method using vaginal dilators and 
the surgical methods consisting of the McIndoe procedure, Vecchietti and Davydov procedures. 
We present a case among other cases in which the McIndoe procedure was successful. Discussion: 
The McIndoe procedure is one of the procedures that have been described as out-dated 
procedures in view of the associated serious risks and complications; with the availability of safer 
laparoscopic procedures, the British Society for Paediatric and Adolescent Gynaecology 
recommends that they are not performed in the UK. However, the McIndoe procedure is still 
being successfully performed in Scotland. This involves the use of a full-thickness skin graft over an 
expandable foam rubber mould placed in the canal between the bladder and rectum. The use of 
the full-thickness skin graft reduces the postoperative contraction previously noted with the split-
thickness skin graft requiring long-term utilization of a vaginal form, which is undesirable if 
unnecessary. Recently, it has been shown that a full-thickness skin graft takes as well as a split-
thickness graft. The main disadvantages are potential vaginal stenosis, perforation of the bladder 
and rectum, graft failure and unsightly scarring at the graft site. Vecchietti method and 
modifications of similar laparoscopic procedure are complicated and technically demanding. All 
these techniques are associated with discomfort and require a long period for adequate results. 
McIndoe procedure is simple and the results are reproducible and it remains one of our preferred 
choices. 
 
 
P-05 Wiebke Birnbaum 
The decision making process in a case of late diagnosed 5a-reductase deficiency 
Birnbaum W, Marshall L, Hiort O 
University of Lübeck 
 
Background: There is a lack of standardization of medical consult within the field of DSD. New 
ethical recommendations have to be considered. Objective We describe a case of 5a-reductase 
deficiency as an example for a complex condition. Our multidisciplinary team was consulted to 
lead the decision-making process. What are the individually tailored steps to ensure a satisfying 
long-term outcome? Methods We present a Kurdish 46, XY girl not diagnosed with 5-ARD until the 
age of 13 1/2 years and sketch the steps which contribute to the informed medical consent. 
Diagnostic evidence was achieved by molecular genetic analysis. We explained 5-ARD and the 
specific implications to the patient and the family attended by a translator. The psychologist 
assessed gender behaviour and identity. Information from the local child protective service 
completed the picture of her social setting. Results All involved parties shared facts, treatment 
options and possible outcomes. The “no treatment” option would lead to irreversible virilisation 
and gender reassignment. The female line would result in gonadectomy and hormone 
replacement therapy. The profound consequences for the patient, her immaturity and the fathers 
ambiguity forbid a finalizing decision at this stage. Hormone suppression allowed a limited 
moratorium to further evaluate gender identity and to empower the patient to consent. A re-
evaluation after 12 months showed a 14 year old teenager with masculine habit and outward 
appearance. She expressed clearly her female gender identity and homosexual orientation. 
Estrogen replacement therapy under hormone suppression initiated female pubertal development. 
Conclusions The management of patients with DSD requires care through specialised 
multidisciplinary centres which analyses the different options and perspectives. This decision takes 
time and is straining. Disclosure process and informed consent management need to be 
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standardised in consideration of patient centred care. Following these guidelines a greater 
compliance with ethical standards will be achieved. 
 
 
P-06 Sally Tantawy 
Analysis of the gene coding for Steroidogenic Factor 1 (SF-1, NR5A1) in a cohort of fifty Egyptian 
patients with 46,XY disorders of sex development 
S. Tantawy1,2, I. Mazen2, H. Soliman3, G. Anwar4, A. Atef4, M. El-Gammal2, A. El-Kotoury2, A. 
Torky2, A. Rudolf1, H. Biebermann1, H. Krude 1, B. Köhler1 
1Department of Pediatric Endocrinology, University Children’s Hospital, Charite´, Humboldt 
University, Berlin, Germany. 2Department of Clinical Genetics, Division of Human Genetics and 
Genome research, National Research Centre, Cairo, Egypt. 3Department of Medical Molecular 
Genetics, Division of Human Genetics and Genome research, National Research Centre, Cairo, 
Egypt.  4Department of Pediatrics, Cairo University, Cairo, Egypt. 
 
Background: SF-1 is a key transcriptional regulator of genes involved in the hypothalamic-pituitary-
gonadal axis. Recently, SF-1 mutations were proved as a frequent cause of 46,XY DSD in humans. 
Objective: To investigate the frequency of NR5A1 mutations in an Egyptian cohort of XY DSD. 
Patients: Fifty Egyptian XY DSD patients (without adrenal insufficiency) with phenotypic spectrum 
of complete female external genitalia with/without uterus (n=8), ambiguous genitalia without 
uterus (n=5), vanishing/atrophic testes (n=10), hypospadias (n=23) and isolated hypoplastic 
phallus (n=4). Methods: Molecular genetic analysis of NR5A1 coding for the SF-1 gene. Results: 
NR5A1 analysis revealed 3 novel heterozygous mutations in 3 hypospadias patients. Patient 1; 
p.Arg62Cys mutation in DBD zinc finger region predicted to result in conformational change of the 
protein. Phenotype: hypoplastic phallus (1 cm at 1 6/12 years), penile hypospadias, hypoplastic 
scrotum, bilateral small inguinal testes, low testosterone, inhibin B and AMH, and high FSH. 
Patient 2; de novo p.Glu121AlafsX25 frameshift mutation producing severely truncated protein. 
Phenotype: hypoplastic phallus (3.5 cm at 13 years), hypospadias, bifid scrotum, unilateral 
cryptorchidism, low testosterone, inhibin B and AMH. Patient 3; p.Ala154Thr hinge region 
mutation predicted to reduce transcriptional capacity of SF-1. Phenotype: hypoplastic phallus (2.5 
cm at 4 years), penile hypospadias, descended testes, mildly decreased testosterone, normal 
inhibin B and AMH. Mutation transmitted from the healthy father. Neither of the 3 patients had 
Müllerian structures. Seventeen patients (34%) harboured p.Gly146Ala polymorphism. Conclusion: 
In our Egyptian cohort we have detected NR5A1 mutations in 3 patients with hypospadias, a 
frequency of 13% compared to 3-5% in European patients (Köhler 2009, Allali 2011). We 
recommend NR5A1 analysis in XY,DSD with hypospadias and partial gonadal dysgenesis. Early 
cryoconservation of sperms in affected males is advised for the risk of progressive gonadal failure 
(Bashamboo 2010, Tantawy 2012). 
 
 
P-07 Yvonne van der Zwan 
Steroidogenic factor-1 mutations: relation with obesity in humans 
Y.G. van der Zwan1, A. Desloovere2, Y.B. de Rijke3, M. Cools2, E.L.T van den Akker1 
1. Department of Pediatrics, Division of Pediatric Endocrinology, Erasmus MC - Sophia, Rotterdam, 
the Netherlands 2. Department of Pediatrics, Division of Pediatric Endocrinology, Ghent University 
and University Hospital Ghent, Ghent, Belgium 3. Departments of Clinical Chemistry and Internal 
Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, the Netherlands 
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Background Steroidogenic factor-1 (SF1) was originally identified as a master-regulator of 
steroidogenic enzymes. SF1 knockout mice showed adrenal agenesis, complete testicular 
dysgenesis, persistent müllerian structures, abnormalities in the ventro–medial hypothalamus 
(VMH) and late–onset obesity. Studies in rodents with lesions of the VMH have shown the role of 
the VMH in body weight and appetite regulation. Others studied the role of the VMH in obesity in 
combination with leptin. Defects in leptin signaling cause severe obesity due to diminished weight 
reducing actions in the brain. Aim To study the relation between SF1 mutations and metabolism 
including obesity. Methods 5 patients with a mutation or deletion of the SF1 gene were included. 
Energy intake and expenditure was measured by a dietician and questioned with the NVE 
questionnaire and the Baecke questionnaire. Sleep pattern was assessed with the SDSC 
questionnaire. Body composition was determined by a DEXA scan. Hormonal evaluation included 
an oral glucose tolerance test, day rhythm of cortisol by saliva sampling, and fasting serum 
concentrations of cortisol and lipids. Results Mean BMI z-score was 1.55 (SD 1.68). For all but one 
patient the energy intake was lower than the calculated energy expenditure. Fat rate of all 
patients was higher than the reference value. Protein intake tended to be higher and carbohydrate 
intake tended to be lower than the calculated need. Fat intake was too high in one patient. Three 
reported sleep problems. Salivary cortisol day rhythms showed normal values. Impaired glucose 
tolerance was noted in one patient. Lipid profiles were all in the normal range. Conclusion We first 
described the relationship between SF1 mutations, metabolism and obesity in humans. 
Preliminary results show a negative relation; energy intake was lower than energy expenditure 
and no weight loss was observed. 
 
 
P-08 Asmahane Ladjouze 
Clinical heterogeneity in patients with NR5A1/ SF1 mutations: About four cases of Algerian 
patients presenting with 46, XY Disorder of sexual differentiation. 
Asmahane Ladjouze1, Foued Abdelaziz2, Pascal Philibert3, Leila Kedj1i, Karima Berkouk1, Yasmine 
Ouarezki4, Charles Sultan3, Abdenour Laraba1 
1Department of Pediatrics, CHU Bab el Oued, Algiers, Algeria 2Department of pediatrics, Guelma, 
Algeria 3Laboratoire d’hormonologie, CHU Montpellier, France 4Department of neonatology, EPH 
Gué de Constantine, Algiers, Algeria 
 
Recently, several heterozygous SF1 mutations have been reported in patients with a wild spectrum 
of 46, XY DSD. We report the cases of 4 patients from two Algerian families, presenting different 
degrees of DSD due to SF1 mutations. Patients 1 and 2 were brothers who were referred 
respectively at birth and 16 months for ambiguous genitalia. They had penoscrotal hypospadias, 
patient 1 had undescended testes. Their karyotype was 46, XY and their genitography revealed the 
presence of Mullerian structures. Testosterone basal levels were low with an impaired response to 
ßHCG. AMH levels were normal in patient 1 but low in patient 2. Analysis of SF1 gene revealed a 
heterozygous mutation (c.370 del C). The brothers were raised as boys and underwent surgical 
treatment. Patients 3 and 4 were 20-day-old twins with apparent female genitalia. Patient 3 was 
referred to our clinic because of clitoral hypertrophy. Pelvic ultrasonography revealed inguinal 
gonads and a the presence of a Mullerian structure. AMH levels were normal for a male and 
testosterone increased slightly after ßHCG. Patient 4 presented female “normal” external and 
internal genitalia and low levels of AMH and testosterone. The karyotype was 46, XY in both sisters. 
A heterozygous mutation of SF1 (c.938G>A) was identified. They had a normal adrenal function. 
Patient 4 deceased at 1 year of age because of purulent meningitis. Initially raised as a girl, patient 
3 was reassigned as a boy at 18 months because of the pressing request of the parents (after a 
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good response to DHT gel and a multidisciplinary discussion). Conclusion: These case reports 
illustrate the phenotypic variability (from complete sexual reversion to isolated hypospadias) of 
SF1 mutations in patients with 46, XY DSD. The question of the sex of rearing remains sometimes 
very difficult with a lot of uncertainties concerning those children’s future. 
 
 
P-09 Nadine Christina Diana Hornig 
Transcription analysis of APOD and PPAP2B in genital skin fibroblasts derived from male controls 
and AIS patients 
N.C. Hornig1,2, J. Oelbe1,  A.E. Kulle1, M. Welzel1, P.M. Holterhus1, R. Siebert2, O. Ammerpohl2, 
G. Wehner3, H.U. Schweikert3, S.L.S. Drop4, M. Cools5, R. Werner6, O. Hiort6 
1Department of Pediatrics, Christian-Albrechts-University Kiel & University Hospital Schleswig-
Holstein, Campus Kiel, Schwanenweg 20, 24105 Kiel, Germany, 2Institute of Human Genetics, 
Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, 
Schwanenweg 24, 24105 Kiel, Germany, 3Med. Klinik III des Universitätsklinikums Bonn, 
Wilhelmstraße 35-37, 53111 Bonn, Germany, 4Department of Pediatrics, Division of Pediatric 
Endocrinology, Molewaterplein 60, 3000 CB Rotterdam, The Netherlands, 5Department of 
Pediatrics, University Hospital Gent, De Pintelaan 185, 9000 Gent, Belgium, 6Department of 
Pediatrics, University of Lübeck & University Hospital Schleswig-Holstein, Campus Lübeck, 
Ratzeburger Allee 160, 23538 Lübeck, Germany 
 
Background: Androgen insensitivity syndrome (AIS) is a X-chromosomal recessive syndrome 
caused by partial to complete resistance of the androgen receptor (AR) to androgens in genetically 
male individuals. While complete AIS is relatively rare (1 in 20,000 live births), partial androgen 
insensitivity (PAIS) is probably the commonest cause of fetal male underandrogenisation. PAIS 
ranges phenotypically from ambiguous genitalia, hypospadias to normal genital development in 
males with infertility. For appropriate counseling, sex assignment and potential prediction of 
puberty development in PAIS it is crucial to determine the individual residual activity of the AR in 
response to androgen. We previously identified APOD and PPA2B as androgen target genes in 
scrotal control tissue, while no upregulation was detected in individuals with complete androgen 
insensitivity syndrome (CAIS). Aim: We aimed at improving our previously published functional 
assay on APOD and PPAP2B in order to investigate AR transcriptional activity in primary genital 
tissue obtained from AIS patients. Methods: Tissue cultures of more than 300 fibroblast cultures 
from male controls and AIS patients are being planned. We have measured APOD and PPAP2B 
transcription in the presence or the absence of dihydrotestosterone under optimized assay 
conditions. Results: Our data confirm that both, APOD and PPAP2B are androgen target genes in 
normal control fibroblasts. AIS samples show variable patterns of inhibited transcription of these 
target genes compared to a strong response in male controls. Discussion: Measurement of 
androgen regulated target genes in genital fibroblasts is of high potential value for the 
characterization of AR function in individuals with AIS. Transcription analyses of APOD and PPAP2B 
in the complete cohort of 300 patients, sequence analyses of the AR gene in each sample as well 
as determination of AR expression are necessary to evaluate the functional role of the two genes 
as biomarkers of AR function in AIS. 
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P-10 Marek Niedziela 
A novel Q117X SRY gene mutation in a 46,XY girl with Swyer syndrome 
M. R. Krawczynski1,2, S. Debicki1,2, K. Kapczuk3,4 , M. Niedziela4,5 
1-Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland, 2-
Center for Medical Genetics GENESIS, Poznan, Poland, 3-Department of Gynecology, Chair of 
Perinatology and Gynecology, , Poznan University of Medical Sciences, Poznan, Poland 4-Karol 
Jonscher’s Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland, 5-
Department of Pediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, 
Poznan, Poland 
 
Background: A 13-year-old normal stature girl with osteoporosis and lack of sexual characteristics 
was admitted to the pediatric endocrine section for diagnostic and therapeutic purposes. Prior 
basal hormonal data confirmed low estrogen level (17 pg/ml), hypergonadotropic hypogonadism 
(LH 42.72 mIU/ml; FSH 154.66 mIU/ml) and 25(OH)D3 deficiency (15 ng/ml) and therefore she was 
referred to the genetic clinic. Routine karyotyping showed 46,XY karyotype with total sex reversal 
and therefore Swyer syndrome was suspected. Aim:To determine the genetic cause of lacking 
secondary sexual characteristics with primary amenorrhea in a 46,XY adolescent girl with 
hypergonadotropic hypogonadism and with a normal renal function Methods: After completing 
clinical, biochemical, hormonal, genetic and imaging examination, the patient underwent 
laparoscopic gonadectomy and simultaneously a direct sequencing of the coding sequence of the 
SRY gene on peripheral blood DNA was performed according to standard procedures. Results: 
Direct sequencing of the coding sequence of the SRY gene enabled to detect a novel nonsense 
Q117X mutation. This mutation leads to premature termination of translation and protein 
truncation in the SRY protein HMG-box and is unequivocally pathogenic. Discussion: It is known 
that HMG-box binds specifically to the AACAAAG double-strand DNA sequence of the male-
specific-genes and in this way regulates their replication and transcription. The critical role in this 
process is played by Ile168 that is lacking in our patient, so the function of the SRY protein is 
completely blocked what fits to the total sex reversal phenotype of the patient. Mutations in SRY 
can lead to diminished expression and function of SRY, resulting in sub-optimal SOX9 expression, 
Sertoli cell formation and subsequent lack of proper testicular development. Conclusions: This is a 
new mutation affecting the SRY gene in 46,XY females with sex reversal and this mutation should 
be considered in genetic counseling. 
 
 
P-11 Scott Shepherd 
One For Dex And Dex For All: Challenges In The Management Of Congenital Adrenal Hyperplasia 
(CAH) In A Multiple Pregnancy 
S.T.C. Shepherd(1), K.J. Cox(1), A. Jackson(2), E. Kinning(3), S.F. Ahmed(1) 
1Child Health, The University of Glasgow, Royal Hospital For Sick Children, Yorkhill, Glasgow, UK 2 
The Neonatal Unit, Princess Royal Maternity Hospital, Glasgow, UK 3 Clinical Genetics, Greater 
Glasgow & Clyde NHS Health Board, Southern General Hospital, Glasgow, UK 
 
Introduction Prenatal glucocorticoid treatment to minimise genital androgenisation in pregnancies 
associated with CAH remains controversial. The likelihood of multiple pregnancies will increase as 
more subfertile adults with CAH seek assisted conception. Case The father of the index cases who 
was subfertile was diagnosed in infancy and required life-long steroid replacement due to a 
homozygous deletion within the CYP21A2 gene. On screening, his partner had a different 
heterozygous mutation in the CYP21A2 gene. Following successful assisted conception and 
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uncertainty about the reliability of prenatal diagnosis in the setting of a twin pregnancy, parents 
declined prenatal diagnosis but opted for empirical treatment with oral dexamethasone 1.5mg 
TDS from week 10 of pregnancy until delivery. An early prenatal ultrasound confirmed a twin 
female pregnancy. Planned caesarean section was performed at 37/40. The birthweight of Twin 1 
and Twin 2 was below the 2nd centile at 1.89kg and 1.96kg respectively. On D4, serum electrolytes 
were within the normal range in both infants but 17-OHP was higher in Twin 1(29nmol/L) than 
Twin 2(3.4nmol/L). Following an uneventful neonatal period, both twins were discharged home on 
Day 5. At Day 13, Twin 1 exhibited mild clitoral prominence and had elevated serum 
androstenedione at 2.7nmol/L and was commenced on glucocorticoid, mineralocorticoid and salt 
supplementation for presumed CAH. On D13, Twin 2 had a sub-optimal peak cortisol of 283nmol/L 
on ACTH stimulation but this had normalised by Wk6. Genetic testing confirmed that Twin 1 had a 
compound heterozygote mutation and Twin 2 was a carrier for the paternal mutation. Discussion 
This case highlights the special challenges faced by clinicians and parents in the setting of a 
multiple pregnancy and a clearer pathway for prenatal management needs to be developed for 
these cases. 
 
 
P-12 Stefan Riedl 
Discrepant biochemical findings in a SRD5A2-mutation-negative patient with 46,XY-DSD showing a 
5-a-reductase deficiency-typical urinary steroid profile 
S. Riedl1,2, A. Springer3, W. Schlegel2, S. Wudy4, O. Hiort5 
1St Anna Children´s Hospital, Department of Pediatrics, Medical University of Vienna, Vienna, 
Austria 2Division of Pediatric Pulmology, Allergology and Endocrinology, Department of Pediatrics, 
Medical University of Vienna, Vienna, Austria 3Department of Pediatric Surgery, Medical 
University of Vienna, Vienna, Austria 4Division of Pediatric Endocrinology and Diabetes, 
Department of Pediatrics, University of Lübeck, Lübeck, Germany 5Steroid Research & Mass 
Spectrometry Unit, Pediatric Endocrinology & Diabetology, Center of Child and Adolescent 
Medicine, Justus Liebig University, Giessen, Germany 
 
Background: Laboratory diagnosis of 5-a-reductase-II-deficiency (5aRD) is usually straightforward 
comprising reduced urinary 5-a metabolites, increased T/DHT ratio after hCG stimulation and 
genetic proof of a SRD5A2 mutation. Aim: We present a 46,XY-DSD patient with discrepant urinary 
versus serum test results in whom no genetic diagnosis has been established so far, for discussion 
on a possible pathomechanism. Case report: An externally female-appearing infant, child from 
healthy and non-consanguineous parents, was diagnosed with 46,XY-DSD in the newborn period. 
Gonads were localised in the inguinal regions and no female internal structures detected. At 3 
weeks T was 1.5 ng/mL and AMH normal at 511 pmol/L. Repeated urinary steroid analyses 
revealed decreased 5-a metabolites, and fibroblast cultures showed decreased DHT generation 
capacity, whereas serum T/DHT after hCG stimulation was normal (T 3.1 ng/mL; T/DHT ratio 3.9). 
Genetic tests for SRD5A2 as well as androgen receptor mutations gave negative results. 
Explorative cystoscopy and laparoscopy revealed inguinal gonads with dissociated epidydimes, 
normal deferent ducts, no female internal structures and a 2 cm blind ending vagina, separating 
from the urethra 1 cm proximal of the opening. The penisoid was slightly enlarged at 1.5 cm. 
Gonadal histology showed testicular tissue with Sertoli-only pattern. The patient, now 12.5 years-
old, has been raised as a girl and entered puberty, LH 0.6 mU/mL, FSH 2.0 mU/mL. No virilisation 
has yet occurred and no increase in testosterone observed (T 0.03 ng/mL), whereas E2 rose (82 
pg/ml) leading to slight breast development (B 2-3). Auxological parameters, apart from 
overweight, have been normal so far and bone-age within the age-related male range. Discussion: 
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As far as no known genetic defect has been elucidated, we suspect a hitherto undescribed 
disorder of the 5-a pathway. The androgen backdoor pathway might play a role. 
 
P-13 Miriam Muscarella 
Words that Matter: Improving Medical Conversations and Resources Around DSD for Patients and 
Families Through Individual Experiences 
M. Muscarella (1), A. Threlkeld (2), K. Luis (3) 
(1) A.B. 2012 Harvard College, 2012-13 Harvard College Pforzheimer Public Service Fellow with 
dsdfamilies.org and University of Glasgow Royal Hospital for Sick Children, (2)MS, 2005, Education, 
Mercy College; Ed.D. 2014 expected, Harvard University 2012-2013 Harvard College Departmental 
Teaching Fellow, Studies of Women, Gender, and Sexuality, (3) Ph.D. 2009, Anthropology, Brandeis 
University 2012-2014 Harvard University College Fellow, Studies of Women, Gender, and Sexuality 
 
Background: Many scholarly works are either critical or unquestioning of medicine’s roles in the 
lives of those with DSDs.  Few published works focus on communication between physicians and 
patients/families by examining diverse and often positive medical experiences of individuals with 
DSD.   
Aim/Objective: This paper seeks to develop new strategies for communication around DSD 
diagnoses and treatments by freshly engaging individual accounts.  
Method: Using thematic analysis of semi-structured interviews with individuals with DSD in 
Australia, this paper integrates the narratives of people with DSD into strategies for enhancing 
collaboration and communication for doctors and support providers. 
Results:  In this qualitative study, seven semi-structured interviews were recorded, transcribed, 
and incorporated into analysis. Four informants identified as having Complete AIS, two identified 
as Partial AIS, and one identified as bladder exstrophy/Partial AIS. All individuals  discussed 
experiences of youth, medical care, and  disclosure.  Emerging themes highlight patient diverse 
experiences and perspectives concerning: timing and tools for disclosure of DSD, medical 
treatments, and discussing gender in the context of a DSD.   
Discussion: These findings offer additional approaches for communication and care around DSD, 
focusing on: disclosure in youth and adulthood, medical care, and gender identity in relation to 
DSD. Findings suggest importance of and strategies for accessible and age-appropriate discussions 
and resources to supplement patient and family’s understandings of karyotype, sex development, 
and DSD." 
 
 
P-14 Soara Menabò 
46,XX DSD with Prader V virilisation, hormonal “conventional” pattern typical for 21-Hydroxylase 
deficiency (21OHD), and lack of CYP21A2 mutations. 
S.Menabò1, L. Baldazzi, G.Cherchi2, G.Cangemi1, M.Mezzullo3, A.Balsamo1 . 
1O.U. Pediatrics, Program of Pediatric Endocrinology, Department of Medical & Surgical Sciences, 
S.Orsola Malpighi Hospital & University of Bologna, Bologna, Italy. 2Azienda Ospedaliero 
Universitaria of Cagliari, Pediatric Clinic, Cagliari, Italy; 3 Endocrinology Unit - Department of 
Medical and Surgical Sciences; Center for Applied Biomedical Research (CRBA). 
 
Background. 46,XX DSD due to CL-11OHD may mimic a patient with CL 21-hydroxylase deficiency 
(CL-21OHD). Objective. To diagnose correctly a 46,XX virilised patient normal to CYP21A2 gene 
analysis. Methods. Conventional RIA and ID-LC-MS/MS measurements, genetic analysis. Patient. 
The female patient, now 1.6 yrs old, was born at term to healthy parents of Sardinian (Italy) origin. 
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At birth she showed virilised external genitalia (Prader stage V) with clitoromegaly, urethral 
meatus at the tip of the organ, complete fusion of labia majora and empty scrotal sac. At 2nd day, 
17-OH-progesterone (21,0 ng/ml), testosterone (2.4 ng/ml) and ?4-A (94 ng/ml) were high. The 
low normal Na (136.8 mEq/L) and slightly high K (5.8 mEq/L) induced to start treatment with 
Hydrocortisone (15 mg/m2/day) and CL 21-OHD was suspected. Ultrasound and 
cystography/cysto-vaginoscopy examinations showed normal Mullerian structures and urogenital 
sinus with regular morphology of the vagina, respectively. Surprisingly, CYP21A2 gene analysis was 
normal. When two months old, the patient was sent to our Centre for diagnostic work up and 
surgical examination. ACTH test performed after two days of treatment withdrawal, showed the 
following basal/stimulated results: cortisol 25.8/28.8 ng/ml, 11deoxycortisol 135.9/187.9 ng/ml, 
DOC 29.9/29.5 ng/ml, D4-A 4.22/5.54 ng/ml, 17OHP 9.13/8.01 ng/ml, DHEA 21.9/21.6 ng/ml, T 
0.52/0.48 ng/ml. The CYP11B1 genetic analysis revealed that the patient is compound 
heterozygous for the paternal novel putative mutation Q337P (CAG>CCG), and the maternal 
variation +148 IVS5 C>G, suspected to create a new donor splicing site. After repeated dialogues 
with parents, at the age of nine months clitoridal-labioplasty was decided. Conclusion. To 
misdiagnosis as 21OHD patients affected by 11OHD may be more frequent than expected. 
Diagnostic hormonal markers should more easily assayed trough the new LC-MS/MS 
methodologies. 17OHP values inappropriate for a CL-21OHD, as in the case presented, should 
make the suspicion of a different enzymatic deficiency. 
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